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                                     INTRODUCTION 
 
      Diabetes is a metabolic disorder of multiple causes characterized by chronic 
hyperglycemia and disorders of carbohydrate, fat, and protein metabolism. It results from  
defects in insulin secretion (type 1), insulin action (type 2), or combination of these  
factors.   Diabetes has become the most common single cause of end-stage renal disease  
(ESRD) in India and worldwide. This is due to the fact that diabetes, in particular type 2  
diabetes, is increasing in prevalence and patients with diabetes are living longer.  
 
                        The World Health Organization  estimated that there were 135  
million diabetics in 1995 and this number would increase to 300 million by the year 2025  
{ref:1}. India leads the world with largest number of diabetic subjects earning the  
dubious distinction of being termed the “diabetes capital of the world”. According to the 
 Diabetes Atlas 2006 published by the International Diabetes Federation, the number of  
people with diabetes in India currently around 40.9 million is expected to rise to 69.9  
millions by 2025( Fig : 2) {ref: 3}. 
                           In the 1970s, the prevalence of diabetes among urban Indians was  
reported  to be 2.1 per cent and this has now risen to 12.1 per cent. Moreover, there is an  
equally  large pool of individuals with impaired glucose tolerance , many of whom  
will develop type 2 diabetes mellitus in the future.{ref: 1} 
                        A national survey of diabetes conducted in six major cities in India in the  
year 2000 showed that the prevalence of diabetes in urban adults was 12.1%. Prevalence  
of IGT  was also high (14.0%) . (Fig: 1) {ref:2} 
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Burden of diabetes related complications in India 
 
.                   A study by  Mohan et al. in South India showed a prevalence of 34.1% of  
retinopathy. The CURES Eye study done in India. showed that the overall prevalence of 
 diabetic retinopathy was 17.6 per cent, which was lower when compared to the reports 
 from the  West .  
              Prevalence of PVD in Asian Indians is comparatively low compared with the 
 white population (9.3%){ref:2} The prevalence of peripheral vascular disease   
was 6.3 per cent among diabetic subjects compared to 2.7 per cent in non-diabetic  
subjects, and these figures are lower than the prevalence reported in western  
populations{ref: 3}. 
 
                        The prevalence of coronary artery disease was 21.4 per cent among 
 diabetic subjects  compared to 9.1 per cent in subjects with normal glucose tolerance. 
 The prevalence of  CAD in IGT subjects were 14.9 per cent in the same study {ref: 3} 
Diabetic nephropathy is one of the leading causes of chronic renal failure in India.  
Among 4837 patients with chronic renal failure seen over a period of 10 years, the  
prevalence of diabetic nephropathy was 30.3% followed by chronic interstitial nephritis  
(23%) and chronic glomerulonephritis  (17.7%){ref:2}. 
                A recent  population based study reported that the prevalence of overt 
 Nephropathy was 2.2 per cent  in Indians while microalbuminuria was present in 26.9  
per cent  Glycated  haemoglobin,  duration of diabetes and systolic blood pressure were  
independently associated with diabetic nephropathy {ref: 3}. 
 
It was estimated that the incidence of renal failure among the south Indian diabetic  
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patients was 0.69% per annum  . A positive association between the D allele (ID and DD  
genotype) of ACE gene  polymorphism and diabetic proteinuria in south Indian type 2  
diabetic patients was  observed which was in agreement with studies in other countries  
showing such an  association. A study had indicated that the risk of CVD was 3-fold 
 higher in nephropathy  group than in the nonproteinuric subjects  {ref:2}. 
 
.                              It is estimated that the annual cost of diabetes care would be 
 approximately 90,200   million rupees. The average expenditure per patient per year  
would be a minimum of   Rs 4,500. {ref:2}. 
 
SOCIO-ECONOMIC INFLUENCES 
                         Prevalence of diabetes was found to be lower in the low socio-economic  
group living in  urban areas compared with the high-income group (12.6 vs 24.6% in  
subjects  years).  This was probably related to the physical activity of the low income  
group  as most  of them were involved in moderate to strenuous physical activity at 
 work.  However due  to inadequate control of diabetes, the long-term complications   
such as coronary artery  diseases were higher in the low socioeconomic group. This was   
to some extent related  to the higher rates of risk factors such as uncontrolled   
diabetes,high cholesterol,  hypertension, smoking and alcohol consumption. {ref:2}. 
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FIGURE 1 
 
Recent population based studies showings the prevalence of type 2 diabetes in 
different parts of India. {ref:3}
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FIGURE : 2 
 
 
Estimated number of diabetic subjects in India {ref:3} 
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DIABETIC NEPHROPATHY 
                              Diabetic nephropathy (DN) is one of the most feared complications of  
both type 1 diabetes mellitus  and type 2 diabetes mellitus . Patients who manifest  
the clinical syndrome of DN (persistent proteinuria and hypertension in association with  
diabetic retinopathy) are not only destined to develop end-stage renal disease (ESRD),  
but are also at increased risk of premature cardiovascular disease and all the other  
complications of diabetes . The development of MA (albumin excretion rate 20–200µg  
per minute) is typically seen five to 15 years after diagnosis and is associated with a rise  
in blood pressure, albeit within the ‘normal range’. Patients subsequently become  
macroalbuminuric (albumin excretion rate (AER) >200µg/min), at which time blood  
pressure is elevated and the other microvascular complications of diabetes emerge. From 
 this point, GFR declines in a linear fashion and, with no intervention, a fall of  
approximately 10ml/min/year leads to ESRD within 10 years. There is an increasing  
focus on detecting the earliest stages of DN in routine clinical practice. A typical example  
is the UK General Practice contract that promotes annual checks of MA in all diabetic  
subjects and the routine estimation of GFR  using the Modification of Diet in Renal  
Disease (MDRD) equation. In patients who screen positive for either or both of these  
tests, more aggressive control of blood pressure is recommended, with a focus on  
inhibition of the renin-angiotensin system  {ref:5}. 
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  Keeping all the above-mentioned issues in mind, this study was conducted  
 to estimate GFR with help of MDRD formula in non –albuminuric  type 1  and  type  2  
diabetic  individuals  for the  early detection of  diabetic nephropathy in   inpatients  
admitted in  department of General Medicine and  Diabetology, Government Rajaji 
hospital, Madurai. . 
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                              REVIEW OF LITERATURE 
DIABETIC NEPHROPATHY 
                       Diabetic nephropathy (DN) is one of the most common disabling  
complications of diabetes mellitus. Characteristically, DN is associated with increased  
proteinuria, hypertension, and progressive loss of renal function. DN can occur in  
individuals with either type 1 diabetes or type 2 diabetes , and if left untreated frequently  
leads to progressive renal structural damage and end-stage renal disease (ESRD).  
Convincing evidence indicates that the rate of progression of both early and late  
nephropathy in patients with type 1 diabetes, and to a lesser extent in type 2 diabetes, can  
be attenuated by multiple interventions 
Pathogenesis of Diabetic Nephropathy 
 
Although both type 1  and    type 2 diabetes mellitus  lead to   ESRD only about 30% of 
patients develop clinically overt nephropathy. The majority of  subjects with diabetes 
escape renal failure, and although some histologic damage occurs  in their kidneys, their 
renal function remains essentially normal until they die.  
Diabetic nephropathy and hypertension are multifactorial disorders that result from  
interaction between both environmental and genetic factors .Polymorphisms of genes  
potentially involved in the genetic predisposition to hypertension, vascular reactivity, and  
insulin resistance, such as those of the renin-angiotensin system, nitric oxide, aldose  
reductase, GLUT I, and lipoproteins, have all been investigated in relation to diabetic  
nephropathy, but studies of candidate genes have, by and large, been inconclusive or, at  
best, have shown weak associations . 
 The red blood cell sodium-lithium countertransport system is a cell-membrane cation  
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transport system whose activity is both genetically determined and increased in essential  
hypertension and is abnormally high in diabetic patients with proteinuria  or  
microalbuminuria . the pathophysiologic relevance of its abnormalities remains uncertain. 
 Sodium-hydrogen antiport activity is increased in a number of cell types from patients 
 with type 1 diabetes with microalbuminuria and proteinuria, as well as in subjects with  
hypertension {ref :6}.  
THE INSULTS: HYPERGLYCEMIA, HYPERTENSION, AND PROTEINURIA 
HYPERGLYCEMIA 
There is no doubt that poor glycemic control is associated with diabetic nephropathy.  
Levels of hemoglobin A1c (HbA1c) are higher in patients with microalbuminuria and  
macroalbuminuria than in those with normoalbuminuria . In humans, the Diabetes  
Control and Complications Trial (DCCT), a prospective multicenter randomized clinical  
trial comparing the effect of intensive and conventional insulin therapy has demonstrated  
that a sustained improvement in HbA1c reduces the risk of development of diabetic  
nephropathy . Similarly, the United Kingdom Prospective Diabetes Study (UKPDS) has  
shown that improved glycemic control is effective in the prevention of microalbuminuria  
in patients with newly diagnosed type 2 diabetes .  
 
Non enzymatic glycosylation 
Sustained hyperglycemia leads to nonenzymatic protein glycation, a posttranslation  
modification that occurs physiologically but is greatly enhanced in hyperglycemic  
conditions. These glycated proteins undergo progressive dehydration, cyclization,  
oxidation, and rearrangement to form advanced glycation end-products (AGEs). Once  
these AGEs are formed, the reaction is not reversible, and they gradually accumulate over  
the lifetime of the protein .  
 17
AGEs directly alter the structural and functional properties of extracellular matrix  
proteins. AGE-mediated protein cross-linking increases matrix rigidity and reduces the  
susceptibility of protein to enzymatic digestion, thus inducing accumulation and  
thickening, and favors trapping of plasma proteins, such as low-density lipoprotein  
(LDL) and immunoglobulin G (IgG). In addition, AGEs can elicit a variety of cellular  
responses by binding to AGE-specific receptors present on many cell types, including  
mesangial cells and tubular epithelial cells . Interaction of AGE-modified proteins with  
the AGE receptors serves to degrade AGE proteins but also induces the synthesis and  
release of cytokines, such as transforming growth factor (TGF-β1), platelet-derived  
growth factor (PDGF), and insulin-like growth factor (IGF), and results in enhanced  
production of collagen, laminin, and fibronectin  
AGE receptor (RAGE) are also expressed on tubular epithelial cells, and it has recently  
been reported that RAGE activation can induce tubular epithelial cell transdifferentiation  
to myofibroblasts, a key event in the development of tubulointerstitial fibrosis. {ref :6} 
THE POLYOL PATHWAY 
In the renal medullary cells, the primary role of aldose reductase seems to be the  
formation of sorbitol, an organic osmolyte, in response to the high salinity in the  
medullary interstitium. It has been argued that, in tissues in which glucose entry into cells  
is insulin independent, more glucose becomes available for reduction by aldose  
reductase, resulting in an increased concentration of sorbitol and/or a reduced  
intracellular concentration of myoinositol.  
 In the polyol pathway, excess sorbitol is oxidized to fructose by the enzyme fructose  
dehydrogenase. The increased ratio of NADH/NAD coupled to the oxidation of sorbitol  
to fructose can result in cellular oxidative stress.  Activation of the polyol pathway is  
more likely to be an epiphenomenon and that other, more central mechanisms are  
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operating in the pathogenesis of diabetic nephropathy. {ref :6} 
 
GLUCOTOXICITY 
Consistent with the finding in clinical studies that hyperglycemia per se plays a key role  
in the development of diabetic kidney disease, studies on both kidney cells and isolated 
 glomeruli have confirmed that high glucose concentrations directly alter extracellular  
matrix deposition. 
In mesangial cells, high glucose concentrations induce cell hypertrophy and increase gene  
expression and protein secretion of extracellular matrix components, such as collagen,  
laminin, and fibronectin . Similarly, levels of type IV and I collagen messenger RNA  
(mRNA) are enhanced in tubular epithelial cells exposed to high glucose concentrations.  
High glucose concentrations enhances GLUT 1 expression by mesangial cells, triggering  
a positive feedback mechanism that may result in progressive damage {ref :6} 
HYPERTENSION 
There is evidence that hypertension plays a critical role in the progression of diabetic  
nephropathy. Indeed the development of proteinuria is paralleled in most cases by a  
gradual rise in systemic blood pressure, and there is a significant correlation between the  
blood pressure levels and the rate of decline in glomerular filtration rate (65).  
In diabetic nephropathy, hypertension is not merely the result of relentless kidney  
damage; Further, prospective studies in both patients with type 1 and type 2 diabetes and  
normal albumin excretion have demonstrated that mean arterial pressure levels are  
significantly higher in those patients who progress to microalbuminuria than in those who  
do not progress . 
Under normal conditions, intraglomerular capillary pressure is tightly regulated by  
precise adjustments in afferent and efferent arteriolar resistance. Hyperglycemia induces 
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 vasodilatation, and in diabetes there is a marked reduction in afferent and a lesser  
reduction in efferent arteriolar resistance. This leads to an increase in levels of glomerular  
capillary pressure and moreover allows ready transmission of any increase in systemic  
blood pressure to the glomerular capillary network . The metabolic and the hemodynamic 
 insults are thus intimately intertwined in determining altered glomerular hemodynamics. 
 The greater efficacy of angiotensin-converting enzyme (ACE) inhibitors in their  
antiproteinuric and renoprotective action as compared with other blood pressure-lowering 
 agents has been in part ascribed to the capacity of ACE inhibitors to reduce glomerular  
capillary pressure by removing the tonic constrictor effect of angiotensin II on the  
efferent arteriole  
when the intraglomerular pressure rises to levels approximating those observed in the  
diabetic and remnant kidney, glomerular volume increases by about 30%. Glomerular  
expansion is associated with the stretching of its structural components, including the  
extracellular matrix and the cellular components.  
. Cyclical stretch stimulates the synthesis and deposition of matrix components, such as  
collagen (I, III, and IV), fibronectin, and laminin, in a manner proportional to the  
intensity of cellular stretch . Interestingly, although cyclical stretch stimulates collagen  
synthesis at all glucose concentrations, net collagen accumulation in the medium can be  
demonstrated only at high glucose levels.. Therefore, the cellular response to a  
hemodynamic insult can be influenced and exaggerated by high glucose concentration in  
the milieu{ref :6}.  
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PROTEINURIA 
In diabetic nephropathy and other progressive glomerulopathies, proteinuria is a strong 
 and independent predictor of decline in renal function . Excessive protein overload  
appears to induce tubulointerstitial damage and hence to contribute to the disease  
progression . Specifically, the excessive tubular reabsorption of proteins and the  
consequent accumulation of proteins in tubular epithelial cells induce the release of  
vasoactive and inflammatory cytokines, such as endothelin-1, osteopontin, and monocyte  
chemoattractant protein-1 (MCP-1). These factors in turn lead to overexpression of  
proinflammatory and fibrotic cytokines and infiltration of mononuclear cells, causing  
injury of the tubulointerstitium and, ultimately, renal scarring and insufficiency . A  
vicious cycle is then established in which changes in renal hemodynamics, either primary  
or in response to nephron loss, induce further proteinuria, perpetuating a mechanism of  
interstitial scarring and loss of more nephrons. The tubular toxicity of protein raises the  
possibility that the beneficial effects of ACE inhibitors in diabetic renal disease may  
reflect their potent antiproteinuric action in addition to the reduction of angiotensin II- 
mediated effects on growth-factor activation and glomerular hemodynamics . Limiting  
protein excretion and the consequent activation of tubular epithelial cell prosclerotic  
signals thus appears instrumental in protecting the kidney from further damage {ref :6} 
 
MOLECULAR MEDIATORS 
To enhance understanding of the pathogenesis of diabetic nephropathy, a number of  
studies have examined the cellular and molecular mechanisms of kidney damage. These  
studies have established the critical concept that the insults of hyperglycemia, high blood  
pressure, and protein overload converge at the cellular level by using similar molecular  
signaling pathways and influencing the expression of common cytokines  
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Transforming Growth Factor-β1 
TGF-β is a ubiquitous cytokine that regulates a variety of cellular processes. It exists in  
three isoforms—TGF-β1, TGF-β2, and TGF-β3—of which TGF-β1 is the best  
characterized and most highly expressed in the kidney. Glomerular and proximal tubule  
cells produce TGF-β1 and express both type I and type II TGF-β receptors, which bind to  
all TGF-β isoforms . 
TGF-β1 has important prosclerotic properties and is a potent inducer of cell hypertrophy  
and apoptosis. In vitro, both glomerular mesangial cells and tubular epithelial cells  
increase their synthesis of collagen, fibronectin, and laminin in response to TGF-β1.  
Furthermore, TGF-β1 inhibits the synthesis of collagenases and stimulates production of  
metalloprotease inhibitors. This results in reduced degradation of extracellular matrix and  
further contributes to accumulation of matrix (85). Finally, in vivo, TGF-β1 induces  
glomerulosclerosis and proteinuria in healthy animals  
The importance of TGF-β1 is further highlighted by in vivo and in vitro studies showing  
that the three key insults implicated in the pathogenesis of diabetic nephropathy promote  
the expression of this cytokine. These studies also suggest that TGF-β1 may have a role  
in the interaction between metabolic and hemodynamic factors in mediating  
accumulation of extracellular matrix in the diabetic kidney. 
High glucose concentrations induce the expression of TGF- β1 in both mesangial and  
tubular epithelial cells. Further, inhibition of TGF-β1 prevents glucose-induced  
hypertrophy of mesangial cells and production of extracellular matrix, indicating that  
these effects are mediated by TGF-β1 via an autocrine mechanism On the other hand,  
TGF-β1 induces the GLUT1 transporter in mesangial cells and can thereby enhance  
glucotoxicity . In vitro, AGEs induce TGF-β1 gene expression and protein secretion by  
mesangial cells , and in vivo administration of AGEs upregulates TGF-β1 in the kidney .  
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Further, TGF-β1 mediates, at least in part, stretch-induced overproduction of mesangial  
matrix . Finally, stretch-induced glucose uptake is also mediated by TGF-β1 . This  
suggests a key role of TGF-β1 as final common mediator of sclerosis and glucotoxicity in  
mesangial cells exposed to metabolic and mechanical perturbations. 
On the basis of this evidence, it is now generally believed that TGF-β1 is the mediator of  
a final common pathway leading to sclerosis in diabetic nephropathy. {ref :6} 
Connective Tissue Growth Factor 
 The importance of CTGF in diabetic nephropathy followed its identification by  
differential cloning as a gene overexpressed in mesangial cells cultured in high glucose  
concentrations . CTGF is only minimally expressed in the normal kidney, but it is  
strongly induced in the mesangium in both human and experimental diabetic nephropathy  
In mesangial cells, CTGF expression is induced by high glucose concentrations,  
mechanical stretch, and TGF-β1 . Furthermore, CTGF is a crucial downstream mediator  
of TGF-β1 signaling, but it appears to mediate selectively the TGF-β1 profibrotic effect  
of increased production of extracellular matrix, whereas it does not have antiproliferative  
and immunosuppressive activity .  
Specifically, CTGF appears to enhance IGF-1 prosclerotic effects, increasing the binding  
of TGF-β1 to its receptors, and to prevent VEGF binding to the KDR receptor . This  
suggests that CTGF may play a role in the pathogenesis of diabetic nephropathy not only  
by acting directly on mesangial cells but also by modulating the activity of other  
cytokines implicated in the pathogenesis of the glomerular damage{ref :6} 
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Growth Hormone and Insulin-like Growth Factor 
IGF-1 stimulates endothelial nitric oxide synthase (eNOS) activity in vitro in endothelial  
cells and induces vasodilation in vivo, and this provides a potential link between IGF-1  
and glomerular hyperfiltration and hypertrophy . In a high-glucose milieu, IGF-1 induces  
the proliferation of mesangial cells, which also may contribute to the glomerular  
hypertrophy of early diabetes. In mesangial cells, IGF-1 increases both matrix production  
and GLUT1 activity , suggesting a role of IGF-1 in glomerulosclerotic process. {ref :6} 
Vascular Endothelial Growth Factor 
Insults relevant to diabetes, such as high glucose, AGEs, mechanical stretch, angiotensin  
II, IGF-1, and TGF-β1, have been shown to induce VEGF production in vitro in  
mesangial cells Moreover, in glomerular epithelial cells, high glucose induces VEGF in a  
TGF-β-1-dependent manner, and stretch stimulates both production of VEGF and  
expression of VEGF receptor . 
Both VEGF and VEGF receptors are overexpressed in the glomeruli in vivo in  
experimental diabetes  and in patients with type 2 diabetes , and plasma VEGF levels are  
raised in patients with type 1 diabetes with nephropathy  
VEGF potently stimulates eNOS expression and activity in cultured endothelial cells ,  
and VEGF blockade normalizes eNOS expression by glomerular capillaries  providing a  
potential link between VEGF and both glomerular hyperfiltration and hypertrophy in  
diabetes. {ref :6} 
Angiotensin II 
 
ACE inhibitors appear to have a greater efficacy than other blood pressure-lowering  
agents in their antiproteinuric and renoprotective action. This has been classically  
ascribed to their effect on glomerular hemodynamics, as suggested by treatments that, by  
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interfering with angiotensin II action, normalize glomerular capillary pressure in diabetic  
rats . 
In particular, angiotensin II can directly induce matrix deposition via a TGF-β1- 
dependent mechanism in both mesangial and tubular cells .High glucose induces  
production of angiotensin II in mesangial cells and stretch magnifies the response of  
mesangial cells to angiotensin II by upregulating the angiotensin II receptor AT1  
.Therefore, in mesangial cells the deleterious effects of hyperglycemia and high  
intraglomerular pressure may result from an enhanced production of and responsiveness  
to angiotensin II. In glomerular epithelial cells, angiotensin II induces apoptosis via a  
TGF-β1-dependent mechanism  . 
In isolated glomeruli, angiotensin II increases glomerular permeability to protein and  
impairs the size-selective function of the glomerular filter. It thus appears that the  
efficacy of ACE inhibitors and angiotensin II receptor antagonists is due not simply to 
 inhibition of the hemodynamic effects of angiotensin II but also to direct blockade of the  
cytokine and growth factor action of angiotensin II. {ref :6} 
 
TRANSCRIPTION FACTORS AND INTRACELLULAR SIGNALING 
PATHWAYS 
. It is  critical to identify the transcription factor or factors implicated in matrix  
overexpression in diabetic nephropathy and to establish which intracellular signaling  
pathways are involved in induction or activation of these transcription factors. 
Nuclear Factor-κB 
The transcription factor NF-κB plays a pivotal role in early gene responses by promoting  
the synthesis of mRNA for various cell-adhesion molecules and cytokines. NF-κB is  
important in cell survival, and its inhibition has been causally related to apoptosis. High  
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glucose, AGEs, angiotensin II, and stretch potently induce NF-κB activation mainly via  
formation of reactive oxygen species and activation of PKC , providing potential cellular  
mechanisms of NF-κB activation in the diabetic kidney. NF-κB is believed to play a key 
 role in proteinuria-induced tubulointerstitial damage in diabetes. Both ACE inhibitors  
and statins are potent NF-κB inhibitors, and their renoprotective action may be related, at  
least in part, to the suppression of NF-κB activity. {ref :6} 
 
Fos, Jun, and the AP-1 Transcription Factor 
c-fos and c-jun are two highly conserved proto-oncogenes. c-Fos and c-Jun proteins  
combine in homo/heterodimers (c-Fos/c-Jun, c-Jun/c-Jun) to form the AP-1 transcription  
complex, which binds to and induces genes with AP-1-binding consensus sequences in  
their promoter regions . Genes encoding for TGF-β1, fibronectin, and laminin contain  
AP-1-binding sites in their promoters; thus, AP-1 may stimulate their transcription and  
induce expression of extracellular matrix protein genes via direct and indirect  
mechanisms . 
 High glucose concentrations and mechanical stretch  induce expression of c-fos and c- 
jun in mesangial cells and is associated with increased transcription of target extracellular  
matrix protein genes via formation of the AP-1 transcription factor. 
Therefore, the AP-1 transcription factor plays an important role in the cascade leading to  
excess deposition of matrix deposition. {ref :6} 
Intracellular Signaling Pathways 
PROTEIN KINASE C 
PKC, a family of ubiquitous serine-threonine kinases, is important in the transduction of  
many extracellular signals.. Both classical and novel PKC isoforms are activated by  
diacylglycerol (DAG) . PKC induces expression of c-fos and c-jun , thus, PKC can be  
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proposed as a potential candidate responsible for the increased AP-1 expression seen in  
diabetic nephropathy.. 
In diabetes, DAG levels are increased and PKC is activated in a variety of tissues,  
including kidney glomeruli . High glucose concentrations lead to de novo DAG synthesis,  
which is then responsible for PKC activation . It is interesting that activation of the DAG- 
PKC pathway in diabetic animals is maintained chronically, and this supports the  
hypothesis of a role of this system in the pathogenesis of chronic diabetic complications.  
Furthermore, glycated products and activation of the polyol pathway can also activate the  
DAG-PKC cascade, suggesting that the activation of DAG-PKC may be a common  
downstream mechanism by which multiple by-products of glucose exert their adverse  
effects . PKC is also a crucial downstream mediator of TGF-β1, angiotensin II, VEGF,  
and cyclic stretch signaling, indicating that PKC activation is a key intracellular target of  
both metabolic and hemodynamic  insults . {ref :6} 
  
.MITOGEN-ACTIVATED PROTEIN KINASES 
Extracellular signal-related kinases (ERK), stress-activated protein kinases (JNK), and 
 p38 kinases (p38) are members of the mitogen-activated protein kinase (MAPK)  
superfamily. These kinases constitute functionally distinct, but structurally related,  
transduction pathways by which extracellular signals are transmitted to the nucleus to  
regulate gene expression. Specifically, MAPKs are activated by phosphorylation at  
specific threonine and tyrosine residues in response to various cytokines and extracellular  
stresses. Activated MAPKs translocate to the nucleus, where they phosphorylate and  
transactivate specific transcription factors, which regulate the expression of c-fos and c- 
jun genes. Thus, MAPKs may influence extracellular matrix protein genes and TGF-β1  
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expression via an AP-1-dependent mechanism . 
Human mesangial cells exposed to stretch show rapid activation of p38, resulting in a  
direct and independent production of fibronectin and TGF-β1; the latter in turn  
contributed to the maintenance of long-term p38 activation in a vicious cycle, resulting in  
the perpetuation of fibronectin accumulation {ref :6} 
 
Clinical definition of diabetic nephropathy  
• Progressive rise in urine albumin excretion. 
• Progressive rise in blood pressure. 
• Eventual decline in glomerular filtration rate and end stage renal failure. 
• In the presence of diabetic retinopathy. 
• Accompanied by progressive rise in cardiovascular risk. 
Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria  
(>300 mg/d or >200 mcg/min) that is confirmed on at least 2 occasions 3-6 months apart. 
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TABLE  -- Pathology of Diabetic Nephropathy in Patients with Type 1 Diabetes and  
Proteinuria 
ALWAYS PRESENT 
 
OFTEN OR USUALLY 
PRESENT 
 
SOMETIMES 
PRESENT 
 
Glomerular basement 
membrane thickening 
 
Kimmelstiel-Wilson nodules 
(nodular glomerulosclerosis) 
global glomerular sclerosis   
focal-segmental 
glomerulosclerosis  , tubular 
glomeruli 
 
Hyaline "exudative" 
leisons (subendothelial)
 
Tubular basement 
membrane thickening 
 
 Capsular drops 
 
Mesangial expansion with 
predominance of 
increased mesangial 
matrix (diffuse 
glomerulosclerosis) 
 
Foci of tubular atrophy 
 
Atherosclerosis 
 
Interstitial expansion with 
predominance of 
increased extracellular 
matrix material 
 
 Glomerular 
microaneurysms 
 
Increased glomerular 
basement membrane, 
tubular basement 
membrane, and Bowman 
capsule staining for 
albumin and IgG 
 
Afferent and efferent 
arteriolar hyalinosis 
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                    Figure 3.  Nodular glomerulosclerosis (diabetic nephropathy) 
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      Figure 4.      Nodular glomerulosclerosis (diabetic nephropathy) 
                          capsular drop. Nodular swelling of the mesangium.
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  Figure .5      Diffuse glomerulosclerosis  ( diabetic nephropathy) 
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NATURAL HISTORY OF NEPHROPATHY 
 
Normoalbuminuria 
Approximately one third of type 1 diabetic patients will have a GFR above the upper  
normal range of age-matched healthy nondiabetic subjects. The degree of hyperfiltration 
 is less in type 2 diabetic patients and reported lacking in some studies. Four factors  
regulate GFR 
.  
Longitudinal studies suggest that hyperfiltration is a risk factor for subsequent increase in  
urinary albumin excretion and development of diabetic nephropathy in type 1 diabetic  
patients but conflicting results have also been reported. The prognostic significance of  
hyperfiltration in type 2 diabetic patients is still debated. Six prospective cohort studies  
investigating normoalbuminuric type 1 and type 2 diabetic patients for 4 to 10 years  
revealed that minimal elevation of urinary albumin excretion, poor glycemic control,  
hyperfiltration, elevated arterial blood pressure, retinopathy, and smoking contribute to  
the development of persistent microalbuminuria and overt diabetic nephropathy Because  
several of those risk factors are modifiable, intervention is feasible{BRENNER} 
 
Microalbuminuria 
 
In addition to hyperglycemia, many other factors can induce microalbuminuria in diabetic  
patients such as hypertension, massive obesity, heavy exercise, various acute or chronic  
illnesses, and cardiac failure 
Alterations in glomerular pressure and flow influence both the diffusive and the  
 33
convecting driving forces for transglomerular passage of proteins Reduction in the  
negatively charged moieties of the glomerular capillary wall, particularly sialic acid and  
heparan sulfhate, have been suggested, but not confirmed Changes in podocyte number  
and morphology have been implicated in the pathogenesis of proteinuria and progression  
of diabetic kidney disease Filtration fraction is presumed to reflect the glomerular  
hydraulic pressure, and microalbuminuric type 1 diabetic patients have elevated filtration  
both at rest and during exercise compared to normal controls 
 Prospective studies have demonstrated that GFR remains stable at normal or  
supranormal levels for at least 5 years if clinical nephropathy does not develop  
Nephromegaly is still present and even more pronounced in microalbuminuric compared  
to normoalbuminuric type 1 diabetic patients. 
Changes in tubular function take place early in diabetes and are related to the degree of  
glycemic control. The proximal tubular reabsorption of fluid, sodium, and glucose is  
enhanced.[208] This process could diminish distal sodium delivery and thereby stimulate  
a tubuloglomerular feedback-mediated enhancement of GFR{BRENNER} 
 
Extrarenal Complications in Diabetic Nephropathy 
Diabetic retinopathy is present in virtually all type 1 diabetic patients with nephropathy, 
 whereas only 50% to 60% of proteinuric NIDDM patients suffer from retinopathy.  
Absence of retinopathy should require further investigation for nondiabetic  
glomerulopathies.. Blindness due to severe proliferative retinopathy or maculopathy is  
approximately five times greater in type 1 and type 2 diabetic patients with nephropathy  
compared to normoalbuminuric patients.Macroangiopathy, for example, stroke, carotid  
artery stenosis, CHD, and peripheral vascular disease are two to five times more common  
in nephropathic patients.. 
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Peripheral neuropathy is present in almost all patients with advanced nephropathy. Foot  
ulcers with sepsis leading to amputation occur frequently (>25%), probably due to a  
combination of neural and arterial disease. 
. over half of the patients with advanced nephropathy had symptoms of autonomic  
neuropathy: gustatory sweating, impotence, postural hypotension, and diarrhea. Diabetic 
 cystopathy is also a frequent (>30%) problem in these patients. {BRENNER} 
 
Diabetic Nephropathy 
Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria  
(>300 mg/24 hours), a relentless decline in GFR, and raised arterial blood pressure.  
While albuminuria is the first sign, peripheral edema is the first symptom of diabetic  
nephropathy. Fluid retention is frequently observed early in the course of this kidney  
disease, that is, at a stage with well-preserved renal function and only slight reduction in  
serum albumin. A recent study suggests that capillary hypertension, increased capillary  
surface area, and reduced capillary reflection coefficient for plasma proteins contribute to  
the edema formation, whereas the washout of subcutaneous interstitial protein tends to  
prevent the progressive edema formation in diabetic nephropathy. 
Most studies dealing with the natural history of diabetic nephropathy have demonstrated  
a relentless, often linear but highly variable rate of decline in GFR ranging from 2 to 20  
mL/minute/year, with a mean of 12 mL/minute/year .Type 2 diabetic patients suffering  
from nephropathy display the same degree of loss in filtration power and in variability of  
GFR. Morphologic studies in both type 1 and type 2 diabetic patients have demonstrated  
a close inverse correlation between the degree of glomerular and tubulointerstitial lesions  
on the one side and the GFR level on the other side.. A reduction in the number of  
restrictive pores leading to loss of ultrafiltration capacity (Kf ) and impairment of  
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glomerular barrier size-selectivity leading to progressive albuminuria and IgGuria in  
diabetic nephropathy.  
Impaired or abolished renal autoregulation of GFR and RPF as demonstrated in type 1  
and type 2 diabetic patients with nephropathy contribute to increase vulnerability to  
hypertension or ischemic injuries of glomerular . More severe diabetic glomerulopathy  
lesions have been documented both during development and progression of renal disease  
in type 2 diabetic patients with the D allele.Furthermore, microalbuminuric type 1  
patients carrying the D allele have an increased progression of diabetic glomerulopathy.  
Nondiabetic glomerulopathy is very rare in proteinuric type 1 diabetic patients, whereas  
this condition is common in proteinuric type 2 diabetic patients without retinopathy. A  
prevalence of biopsies with normal glomerular structure or nondiabetic kidney diseases  
of approximately 30% was demonstrated.   
Systemic blood pressure elevation to a hypertensive level is an early and frequent  
phenomenon in diabetic nephropathy. Furthermore, nocturnal blood pressure elevation  
("non-dippers") occurs more frequently in type 1 and type 2 diabetic patients with  
nephropathy {BRENNER} 
 
Changing natural history of diabetic nephropathy  
Microalbuminuria generally appears within 5–15 years’ duration of diabetes. Without  
specific intervention, over approximately a further 10 years, dipstick positive or  
conventional proteinuria is present. when, untreated, there is a progressive decline in  
glomerular filtration over a further 10 years, until end stage renal failure is reached..  
The cumulative incidence of microalbuminuria and proteinuria in several more recent  
studies is 35%–40% and 25% respectively after 25–30 years of diabetes {ref :10} 
In white individuals, the development of diabetic nephropathy follows a similar course to  
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that in type 1 diabetes.. 
In non-white individuals, the cumulative risk of nephropathy is almost certainly higher  
and the disease may develop more rapidly than in white people  
An estimated 5% to 15% of DM 2 cases also progress through the five stages of diabetic  
nephropathy (DN), but the timeline is not as clear. Some patients advance through the  
stages very quickly. {ref :10} 
Type 1 and white type 2 diabetic patients 
    Microalbuminuria develops at a rate of 2%–3% per annum. 
          The cumulative incidence of microalbuminuria is 50% over a life time of diabetes. 
         One third of microalbuminuric patients progress to proteinuria. 
    Almost all proteinuric patients develop end stage renal disease or die prematurely of   
     cardiovascular disease. 
    Long duration patients may not be protected. 
Non-white type 2 diabetic patients 
         Microalbuminuria develops at a rate of 4% per annum. 
         The cumulative incidence of microalbuminuria is 50% at 20 years’ duration  
        of diabetes. 
        Progression from microalbuminuria to proteinuria and end stage renal disease may  
        occur faster than in type 1 diabetes {ref :10} 
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CLINICAL STAGING OF DIABETIC NEPHROTHY 
Stage 1 (very early diabetes) Increased demand upon the kidneys is indicated by an  
above-normal glomerular filtration rate (GFR)  
Stage 2 (developing diabetes) The GFR remains elevated or has returned to normal, but 
 glomerular damage has progressed to significant microalbuminuria (small but above- 
normal level of the protein albumin in the urine). Patients in stage 2 excrete more than 30  
mg of albumin in the urine over a 24-hour period 
Stage 3 (overt, or dipstick-positive diabetes) Glomerular damage has progressed to  
clinical albuminuria. The urine is "dipstick positive," containing more than 300 mg of  
albumin in a 24-hour period.  (high blood pressure) typically develops during stage 3.  
 
Stage 4 (late-stage diabetes) Glomerular damage continues, with increasing amounts of  
protein albumin in the urine. The kidneys' filtering ability has begun to decline steadily,  
and blood urea nitrogen (BUN) and creatinine (Cr) has begun to increase. The glomerular  
filtration rate (GFR) decreases about 10% annually. Almost all patients have  
hypertension at stage 4.  
Stage 5 (end-stage renal disease, ESRD) GFR has fallen to approximately 10 milliliters  
per minute (<10 mL/min) and renal replacement therapy (i.e., hemodialysis, peritoneal  
dialysis, kidney transplantation) is needed.  
Progression through these five stages is rather predictable because the onset of DM 1 can  
be identified, and most patients are free from age-related medical problems. {ref :10} 
 
From the literature search a number of potential risk factors were. A variety of potential  
risk factors were assessed in studies of longitudinal design. These were: 
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blood glucose levels,  blood pressure levels, smoking , lipids,  body mass index ,age ,sex ,  
baseline albumin excretion , duration of diabetes , retinopathy. 
Three other risk factors; homocysteine, family history, race were identified only by cross  
sectional studies.{ref:11} 
 
 
TABLE  Risk Factors and Markers for Development of Nephropathy in Type 1 and 
Type 2 Diabetic Patients 
 
RISK FACTORS   /  MARKERS                                                     TYPE 1       TYPE2   
Normoalbuminuria (above median)       +       + 
Microalbuminuria       +       + 
Sex M > F M > F 
Familial clustering       +       + 
Predisposition to arterial hypertension       ±       + 
Increased sodium/lithium counter transport       ±      -- 
Ethnic conditions       +       + 
Onset of IDDM before age 20 yr       +       ? 
Glycemic control       +       + 
Hyperfiltration       ±       ± 
Prorenin       +       ? 
Smoking       +       ? 
Cholesterol       +       + 
Presence of retinopathy       +       + 
{Ref:Brenner} 
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SCREENING FOR DIABETIC NEPHROPATHY AND MONITORING 
RENAL FUNCTION 
Clinical Practice Guidelines  for Diabetes and Chronic Kidney Disease (CKD) 
{REF;13} 
 Screening and Diagnosis of Diabetic Kidney Disease (DKD) 
CKD in patients with diabetes may or may not represent DKD. In the absence of an  
established diagnosis, the evaluation of patients with diabetes and kidney disease should  
include investigation into the underlying cause(s). 
 Patients with diabetes should be screened annually for DKD. Initial screening should  
commence: 
• 5 years after the diagnosis of type 1 diabetes;  or 
• From diagnosis of type 2 diabetes.   
 Screening should include: 
• Measurements of urinary albumin-creatinine ratio (ACR) in a spot urine  
      sample;  
• Measurement of serum creatinine and estimation of glomerular filtration  
     rate (GFR).  
 An elevated ACR should be confirmed in the absence of urinary tract infection with 2  
additional first-void specimens collected during the next 3 to 6 months.  
• Microalbuminuria is defined as an ACR between 30-300 mg/g. 
• Macroalbuminuria is defined as an ACR >300 mg/g. 
• 2 of 3 samples should fall within the microalbuminuric or macroalbuminuric range 
      to confirm classification. 
 In most patients with diabetes, CKD should be attributable to diabetes if: 
• Macroalbuminuria is present;  or 
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• Microalbuminuria is present  
• In the presence of diabetic retinopathy  
• In type 1 diabetes of at least 10 years' duration  
 Other cause(s) of CKD should be considered in the presence of any of the following  
circumstances:  
• Absence of diabetic retinopathy 
• Low or rapidly decreasing GFR 
• Rapidly increasing proteinuria or nephrotic syndrome 
• Refractory hypertension 
• Presence of active urinary sediment 
• Signs or symptoms of other systemic disease; or 
• >30% reduction in GFR within 2-3 months after initiation of an angiotensin- 
      converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB). 
 
. 
 As ACR may be elevated with conditions other than diabetic nephropathy, such as recent  
major exercise , fever , urinary tract infection, congestive heart failure , acute severe  
elevations of blood pressure (BP) or blood glucose (BG) , or menstruation, screening for  
microalbuminuria should be delayed in the presence of these conditions. 
Creatinine clearance, an estimate of the kidney’s ability to filter toxins from the blood,  
should be determined by a formula such as the Cockcroft-Gault formula or Modification  
of Diet in Renal Disease (MDRD) formula  rather than by serum creatinine, which may  
falsely indicate that a person’s renal function is normal .  
Cross sectional studies appear to show that cystatin C rises out with the reference range  
before serum creatinine and correlates better with iohexol glomerular filtration rate than  
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creatinine clearance or glomerular filtration rate calculated by the Cockcroft-Gault  
equation. Cystatin C is assayed by an automated immunoturbidimetric assay, so that it  
would be applicable to routine clinical practice if longitudinal studies confirm its promise. 
 
Management of Hyperglycemia and General Diabetes Care in CKD 
Hyperglycemia, the defining feature of diabetes, is a fundamental cause of vascular  
target-organ complications, including kidney disease. Intensive treatment of  
hyperglycemia prevents DKD and may slow progression of established kidney disease. 
 Target hemoglobin A1c (HbA1c) for people with diabetes should be <7.0%, irrespective  
of the presence or absence of CKD.  
 
Management of Hypertension in Diabetes and CKD 
Most people with diabetes and CKD have hypertension. Treatment of hypertension slows  
the progression of CKD. 
 Hypertensive people with diabetes and CKD stages 1-4 should be treated with an ACE  
inhibitor or an ARB, usually in combination with a diuretic.  
 Target blood pressure in diabetes and CKD stages 1-4 should be <130/80 mmHg.  
 
Management of Dyslipidemia in Diabetes and CKD 
Dyslipidemia is common in people with diabetes and CKD. The risk of cardiovascular  
disease (CVD) is greatly increased in this population. People with diabetes and CKD  
should be treated according to current guidelines for high-risk groups. 
 Target low-density lipoprotein cholesterol (LDL-C) in people with diabetes and CKD  
stages 1-4 should be <100 mg/dL; <70 mg/dL is a therapeutic option.  
People with diabetes, CKD stages 1-4, and LDL-C >100 mg/dL should be treated with a  
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statin.  
Treatment with a statin should not be initiated in patients with type 2 diabetes on  
maintenance hemodialysis therapy who do not have a specific cardiovascular indication  
for treatment. 
Nutritional Management in Diabetes and CKD 
Management of diabetes and CKD should include nutritional intervention. Dietary  
modifications may reduce the progression of CKD. 
 Target dietary protein intake for people with diabetes and CKD stages 1-4 should be the  
recommended daily allowance (RDA) of 0.8 g/kg body weight per day. 
 
Management of Albuminuria in Normotensive Patients With Diabetes and  
Albuminuria as a Surrogate Marker 
Normotensive people with diabetes and macroalbuminuria should be treated with an ACE 
 inhibitor or an ARB.  
 Treatment with an ACE inhibitor or an ARB may be considered in normotensive people  
with diabetes and microalbuminuria.  
 Albuminuria reduction may be considered a treatment target in DKD 
Multifaceted Approach to Intervention in Diabetes and CKD 
The care of people with diabetes and CKD should incorporate a multifaceted approach to  
intervention that includes instruction in healthy behaviors and treatments to reduce risk  
factors.  
 Target body mass index (BMI) for people with diabetes and CKD should be within the  
normal range (18.5-24.9 kg/m2).  
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Diabetes and CKD in Special Populations 
Screening and interventions for diabetes and CKD should focus on populations at greatest 
 risk.  
 Although management of diabetes and CKD in special populations should follow the  
same principles as management in the majority population, there are special  
considerations in the treatment of children, adolescents, and the elderly.  
 Population-based interventions may be the most cost-effective means for addressing the  
burden of CKD in special populations. Implementation and evaluation of population- 
based interventions should take into account the heterogeneity of the populations at risk.  
 Specialists in high-risk pregnancy and kidney disease should co-manage pregnancy in  
women with diabetes and CKD.  
 Treatment of DKD with renin-angiotensin system (RAS) inhibitors before pregnancy  
may improve fetal and maternal outcomes, but these medicines should be discontinued as  
soon as a menstrual period is missed or after a positive pregnancy test.  
 Insulin should be used to control hyperglycemia if pharmacological therapy is necessary  
in pregnant women with diabetes and CKD.  
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Behavioral Self-Management in Diabetes and CKD 
 Self-management strategies should be key components of a multifaceted treatment plan  
with attention to multiple behaviors:  
• Monitoring and treatment of glycemia 
• Blood pressure 
• Nutrition 
• Smoking cessation 
• Exercise 
• Adherence to medicines 
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                                         AIMS AND OBJECTIVES 
 
 
TO ANALYSE GLOMERULAR FILTERATION RATE IN NON ALBUMINURIC 
 
 TYPE 1 AND TYPE 2 DIABETES MELLITUS PATIENTS, DEFINED AS  
                                                                                                                                                                                  
GLOMERULAR FILTERATION RATE LESS THAN 90 ML/MIN PER 1.73M 2 
 
BODY SURFACE AREA FOR EARLY DETCTION OF CHRONIC KIDNEY  
 
DISEASE . 
 
. 
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MATERIALS AND METHODS 
Setting  :  All patients of type 1 and type 2 diabetes mellitus admitted in  Department 
of Medicine and  Department of Diabetology  GRH, Madurai.  
Collaborating Departments    : Department of  Nephrology  
       Madurai Medical College 
       Madurai.  
                                                          Department of Diabetology 
                                                          Madurai Medical College 
                                                          Madurai 
       Department of Biochemistry 
       Madurai Medical College  
       Madurai 
 
Design of the study     : Cross-sectional study 
Period of study      : 01.12.2005 – 30.09.2007 
 Sample size         :  Type 1 Diabetes mellitus- 25 
                                                       :  Type 2 Diabetes mellitus - 161 
Ethical committee approval  : Obtained  
Consent     : Informed consent was obtained  
Financial support     : Nil  
Conflict of interest    : Nil  
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DEFINITION OF DIABETES MELLITUS 
 
The criteria for the diagnosis of diabetes are as follows: 
 
Symptoms of diabetes associated with 
 
a. Random plasma glucose concentration ≥ 200 mg/dl 
 
b. Fasting  plasma glucose ≥ 126 mg/dl 
 
c. 2 hr plasma glucose ≥ 200 mg/dl during a 75 g OGTT. 
 
For asymptomtic individuals with any one of the above values, a 75 g OGTT is required  
 
to confirm the diagnosis. Random is defined as any time of day with out regard to time 
 
 since the last meal. The classic symptoms of diabetes include polyuria, polydipsia,  
 
Polyphagia and unexplained weight loss, Fasting is defined as no caloric in take for at  
 
least eight hours 
 
DEFINITION OF RETINOPATHY 
 
The diabetic retinopathy was classified as absent retinopathy, background retinopathy, 
 
and proliferative  retinopathy  and was  assessed  by fundoscopy.( fig.6 to fig.14) 
 
 
QUANTIFICATION OF ALBUMINURIA 
 
 
 
  Urine collection method Normal Microalbuminuria
 Albuminuria or clinical 
  proteinuria 
Total 
Protein 
24-Hour Excretion (varies 
with method) 
<300 
mg/day 
         NA         >300 mg/day 
  Spot Urine Dipstick <30 
mg/dL 
         NA          >30 mg/dL 
  Spot Urine 
Protein-to-Creatinine Ratio 
(varies with method) 
<200 
mg/g 
          NA         >200 mg/g 
Ref ;Schrier, Robert W. Title: Diseases of the Kidney & Urinary Tract, 8th Edition  
     Copyright Â©2007 Lippincott Williams & Wilkins 
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      Figure.6 MINIMAL NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) -- FEW 
SCATTERED MICROANEURYSMS (m) ONLY, THE REMAINDER OF THE FUNDUS IS 
NORMAL. 
 
                          
Figure.7 MILD NON-PROLIFERATIVE DIABETIC RETINOPATHY -- MICROANEURYSMS 
(m) AND DOT HAEMORRHAGES (h). ALSO DEMONSTRATES MACULAR OEDEMA WITH 
A SMALL AMOUNT OF LIPID EXUDATE (e) -- NOT CLINICALLY SIGNIFICANT. 
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Figure.8  MODERATE NON-PROLIFERATIVE DIABETIC RETINOPATHY -- COTTON 
WOOL SPOTS (w) RETINAL HAEMORRHAGES (h) AND MICROANEURYSMS (m) 
 
                 
Figure.9 SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY -- INTRARETINAL 
MICROVASCULAR ABNORMALITIES OR IRMA (i) VENOUS READING (b) OR VENOUS 
CALIBER CHANGES, WIDESPREAD RETINAL ISCHAEMIA AND COTTON WOOL SPOTS 
(w) -- BEGINNING OF NEW VESSEL ON OPTIC DISC. 
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Figure.10 PROLIFERATIVE DIABETIC RETINOPATHY -- PERIPHERAL NEW VESSEL (v), 
RETINAL HAEMORRHAGES (h) AND NO VITREOUS OR PRE-RETINAL HAEMORRHAGE 
-- NOTE LACK OF OTHER RETINOPATHY FEATURES  
 
            
 
Figure.11 HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY -- LARGE FROND OF 
DISC NEW VESSEL (v) AND PRE RETINAL HAEMORRHAGE 
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  Figure.12    HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY POST 
TREATMENT WITH PAN-RETINAL LASER PHOTOCOAGULATION SCARS (s) 
TEMPORARILY AND NASALLY -- DISC NEW VESSELS REGRESSED  
 
                              
 
Figure.13 ADVANCED PROLIFERATIVE DIABETIC RETINOPATHY PRERETINAL 
FIBROVASCULAR TISSUE PRODUCING TRACTION ON RETINA (f) ACROSS THE 
MACULAR REGION 
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            Figure.14   CLINICALLY SIGNIFICANT MACULAR OEDEMA LOCALIZED AREA OF 
RETINAL OEDEMA SURROUNDED BY LIPID EXUDATES (E) EXTENDING TO THE 
MACULA 
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Estimation of GFR  
The GFR per 1.73 m2 BSA was calculated with serum creatinine, urea nitrogen, and  
albumin levels using an equation developed from the Modification of Diet in Renal  
Disease (MDRD) Study, as follows: 
 GFR = 170  x  [serum creatinine]-0.999 x  [age]-0.176 x   [0.762 if female]  x  
[1.180 if non Hispanic black]  x  [blood urea nitrogen]-0.170 x  [serum albumin]-0.318  
 
The MDRD GFR calculator was available from internet at the following address 
http://www.nephron.com/MDRD_GFR.cgi and was utilized to calculate GFR. 
Selection and Details of Study subjects 
 Out of  406 diabetic individual evaluated during the study period 73 were excluded due 
to elevated sr.creatinine, 75 had macro proteinuria, 57 was diagnosed to have micro 
albuminuria and 25 were eliminated since they were on ACEI / ARBS. Leaving 186 
patients for study .Type 1  DM  comprised 25 patients and  161 came under Type 2 DM 
category  respectively. Data were collected in a cross-sectional way during their hospital 
stay . Patients were initially screened with early morning urine for spot protein creatinine 
ratio and  then based on absence of macro proteinuria  24 hrs urinary protein was done to 
assess the presence of any   significant proteinuria..The test was repeated 3 times and 
average of three was taken as absence of significant proteinuria. Optic fundus was studied 
with ophthalmosope and assessed for retinopathy. Blood pressure was measured with 
mercury manometer and average of 6 BP recordings were taken  for analysis.  Sr. 
creatinine and blood glucose were analysed  using  ERB 300 full auto analyzer. 
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Haemoglobin was estimated using coulter counter. Urine protein was analysed  using 
auto analyzer.  Data was analysed with MINITAB 15 statistical software .cross tabulation 
and chi square  analysis  was done using the variables recorded. 
 
Inclusion criteria  
TYPE 1 DM AND TYPE 2DM 
1.40 years of age or older and completed a standardized interview and a detailed physical  
 
examination and classified as having type 2 DM according to the American Diabetes  
 
Association (ADA) 
 
2. Type 1 with a duration of at least 10 years 
 
3. Normoalbuminuria  
 
4. serum creatinine <2.0 mg/dl  
 
5. Absence of clinical  evidence of other glomerulopathies. 
  
Exclusion criteria  
Patients known to be microalbuminuric before antihypertensive therapy was started  were  
 
not eligible for this study and those who were on ACEI / ARBS were excluded. 
 
Patients with urinary tract infection, congestive heart failure , acute severe elevations of  
 
blood pressure  or blood glucose  or  menstruation  urine samples were taken  after the  
 
patients had recovered from the acute illness. 
 
Symptoms interviewed for : 
 
Polyuria, polydipsia, polypaghia 
 
Weight loss 
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Chest pain ,palpitation, breathlessness, 
 
Swelling of lower limbs, facial puffiness, 
 
Dysuria, oliguria, hematuria, 
 
Pruritis vulva, 
 
Pins and needles burning sensation in extremities 
 
Foot infection, amputation, diabetic foot, 
 
Diminison of vision 
 
Acute complications ( DKA, hypoglycemia, hyperosmolar state, cereberovascular  
 
accidents, myocardial infarction, unstable angina,Non-STEMI,) 
 
Absent sweating,postural giddiness, chronic diarrhea or constipation. 
    
History of cardiovascular events (e.g, myocardial infarction, other acute coronary 
 
 syndromes),hypertension, peripheral vascular disease, retinopathy, smoking, alcohol  
 
consumption, intake ACEI  medication. 
 
              EXAMINATION: 
 
              Height, weight., waist circumference, 
 
              Pulse,peripheral pulses,   
 
              Blood pressure ( mean of 6 readings) ,postural drop of BP. 
 
              DEFINATION 
                                                             Systolic                                     diastolic  
 
                  High normal                      130--139                                   90—99 
 
                 Hypertension  
 
              Stage I (mild )                       140—159                                  90—99 
 
              Stage II (moderate)               160—179                                100—109 
  
              Stage III ( Severe)                  >180                                          > 110 
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              Isolated systolic                      >140                                          <90 
 
              hypertension 
 
 
              RETINOPATHY 
                    
                        I .Normal fundus 
 
                       II. Background retinopathy 
                
                     III. Proliferative  retinopathy 
 
 
Investigation 
 
              Blood Hb   in  gm%: 
 
Urine for sugar , albumin, deposit, 
 
Blood glucose, blood urea, sr, creatinine 
 
Lipid profile 
 
Urine spot protein creatinine ratio, 
 
24 hrs urinary protein ( average of three samples ) 
 
I .More   than  300mg/24 hrs – proteinuria 
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RESULTS: 
 
                Out of 186  patients 161 were categorized to Type2 DM and  25  to Type 1 
DM. Among males 14( 13%) were type 1 DM and 97 (87%) were type 2 DM .  11 (14%)  
females  fell under the category of type 1 DM and  64 (86% ) in type 2 DM ( table 1). 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         TABLE 1 .TYPE OF DIABETES MELLITUS AND SEX DISTRIBUTION  
  
       
 
 
  
  
  
   
 
                 
           TABLE 2 
 
          SEX   DISTRIBUTION ACCORDING TO GFR IN TYPE 1 DM AND TYPE 2 DM 
The mean age was 53 ± 13 years among the total study group and the mean duration of 
illness was 6 ± 7years.  15 patients under type 1 DM and 133 patients under type 2 DM 
had GFR < 90ml/min.( table 2) 
 
 
 
 
MALE FEMALE S.NO TYPE OF 
DIABETES 
MELLITUS NO. % NO. % 
1. TYPE  1 
 
14 12.61 11 14.67 
2. TYPE 2 
 
97 87.39 64 85.33 
 TOTAL 111 100 75 100 
     TYPE 1DM 
         GFR   in ml/min      
     TYPE 2DM  
        GFR in ml/min 
 
 >90 60-89 30-59 >90 60-89 30-59 
MALE  5 2 7 20 19 58 
FEMALE  5 1 5 8 18 38 
TOTAL 10 3 12 28 37 96 
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Figure: 15   Graph depicting the distribution of type of diabetes , sex and stages of  
 
                  chronic kidney disease 
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                TABLE 3 . DURATION OF DIABETES IN  BOTH TYPES OF DIABETES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
  
                  
DM- DIABETES MELLITUS 
 
 
 
Among  Type 1 DM  14  (64%) patients had duration of diabetes for 11—15 years  with  
 
mean duration of illness  15 ( ± 6)years  with maximum  of 35 years.( table .2) 
In type 2 DM  66( 41.2 % ) patients  was recently diagnosed with mean duration of    
5 (± 6)  years  and maximum of 34 years.( table.3) 
 
 
              
                 
      TYPE 1 
DM 
         TYPE 2 DM 
 
 
DURATION OF 
ILLNESS 
No.        % No         % 
Recently 
Diagnosed 
-     - 66 41.250 
1—5 yrs -    - 37 23.125 
6—10yrs -    - 32 20 
11—15yrs 16 64 16 10 
16—20yrs 4 16 7 3.75 
20---25yrs 2 8 1 0.625 
25—30yrs 2 8 1 0.625 
30—35yrs 1 4 1 0.625 
TOTAL 25 100 161 100 
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                 TABLE 4 .  DIABETES AND CARDIOVASCULAR MORBIDITY 
 
 
 
 
 
          
  
             
 CAD- CORONARY ARTERY DISEASE 
            MI- MYOCARDIAL INFARCTION  
93%  of  males in type 2 DM  had cardiovascular symptoms, while  only 6.9% of type 2  
DM  patients  had similar symptoms.  88.9% of females under type 2 DM and 11% in  
type 1 DM  category had  clinical symptoms pertaining to cardiovascular illness.(table .3) 
52% of males and 47% of females in type 2 DM group had revealed as they were  
suffering  from hypertension. None of type 1  DM  patients gave history of hypertension 
ref: table .3. 
72% of males and 27% of females in type 2 DM  had  acute coronary events either in the  
form of myocardial  infarction or unstable angina. There were no similar events recorded  
under type 1 DM category. (table.4)   
 SYMPTOMS  TYPE 1DM TYPE 2 DM 
M 3 6.9% M 40 93.1%1 Cardiovascular 
Symptoms F  3 11.1% F 27 88.9%
M 0 0% M 28 52.8%2. History of Hypertension 
F 0 0% F 25 47.2%
M 0 0% M 32 72.7%3 History CAD/ MI 
F 0 0% F 12 27.3%
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          TABLE.5 TYPE OF DIABETES, SEX, CAD/MI IN RELATION TO GFR 
 
 
 
 
 
 
 
 
 
 
 
              CAD- CORONARY ARTERY DISEASE 
              MI- MYOCARDIAL INFARCTION  
 
   9 patients in type 1 DM and 79 patients in type 2 DM had GFR  less than 90 ml/min. 
 7 patients in type 1 DM and 58 patients in type 2DM had  GFR  <60 ml/min.( table 5) 
       TYPE 1 DM 
        CAD/ MI   IN  
RELATION TO  GFR     
     TYPE 2 DM  
        CAD /MI  IN 
RELATION TO GFR 
 
 >90 60-89 30-59 >90 60-89 30-59 
MALE  0 0 0 10 3 19 
FEMALE 5 2 7 10 18 39 
TOTAL 5 2 7 20 21 58 
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                TABLE 6.   DIABETIC PERIHERAL NEUROPATHY AND 
                                     DIABETIC FOOT 
             
  
 DM-DIABETE MELLITUS        
   
65% of type 2 DM males and 50% of type 1 DM males had symptoms of sensory 
disturbances over distal extremites  while 50%  of  type 1 DM  females and 34% of  
females diseased with type 2 DM had similar symptoms. 
77% of type 2 DM males  and 23% of type 2 DM females  had peripheral vascular  
disease in the form of feeble or absent peripheral pulses. None of the type 1 DM  patients  
suffered from similar complaints. 
78% of type 2 DM males and 22% of type 2 DM females had longstanding non healing 
 foot ulcers.. None of type 1 DM individuals had similar situation. ( table 6) 
 SYMPTOMS  TYPE 1 DM TYPE 2 DM 
M 3 50% M 25 65.8% 1 Symptoms of diabetic 
neuropathy F  3 50% F 13 34.2% 
M 0 0% M 20 77% 2. Peripheral vascular 
 disease F 0 0% F 6 23% 
M 0 0% M 18 78.2% 3 History of non healing 
foot ulcers F 0 0% F 5 21.8% 
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                  TABLE 7. ACUTE COMPLICATIONS OF DIABETIC PATIENTS 
                                    IN STUDY  POPULATION 
 
 
 
 
         Non-STEMI-non ST elevation myocardial infarction 
 
   The   prevalence of acute complication  among type 1 DM  was 12% and 27.9% in type  
2 DM .Diabetic ketoacidosis occurred in  6.45% in both groups.   4.3% had  
hypoglycemia and 5.38%  of patients had cereberovascular  accidents.  Myocardial  
infarction was the presenting complication in 4.84% of both categories. Acute coronary  
syndrome in the form of unstable angina and Non- STEMI happened in 3.76% of  
patients. Overall complications  in  both groups was 25.8%.  Males  encountered  15.05%  
and  females had  10.75% complications. (table. 7).( figure ;16) 
TYPE1 
DM 
  TYPE 2 
DM 
CUMULATIVE     S.NO COMPLICATIONS 
total % total % M F total % 
1. Diabetic ketoacidosis 2 8 10 6.2  7 5 12 6.45 
2. Hypoglycemia 1 4 7 4.3  5 3 8 4.3 
3. Cereberovascular 
 Accident 
0 0 10 6.2  7 3 10 5.38 
4. Myocardial infarction 0 0 9 5.6  7 2 9 4.84 
5. Non-STEMI /  
Unstable angina 
0 0 7 4.3  1 6 7 3.76 
6. Hyperosmolar coma 0 0 2 1.2  1 1 2 1.07 
 total 3 12 45 27.9 28 20 48 25.8 
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Figure 16:  Graph depicting the distribution of acute complications encountered by study 
                 population
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                       TABLE 8 RETINOPATHY IN  THE DIABETIC PATIENTS 
                                         IN STUDY GROUP 
  
 
 
 
 
  DM-- DIABETES MELLITUS 
 
 
Fundus examination   revealed  only 24% background retinopathy and no  findings  
 
suggestive of proliferative  retinopathy in type 1 DM  . Among type 2 DM  21.1% had  
 
background retinopathy   and 6.8% had proliferative  retinopathy. Retinal study  could  
 
not be done  in 29.6% due to mature cataract. While comparing  sex  preponderance  
 
males  had  15.59%  and  females  11.82%  accounting for a total 27.4% of diabetic  
 
retinopathy in both the groups  of study population.(table 8) 
 
 
TYPE1 
DM 
  TYPE2 
DM 
CUMULATIVE     S.NO COMPLICATIONS 
total % total % M F total % 
1. CATRACT 0 0 55 34.2 29 26 55 29.6 
2. NORMAL FUNDUS 19 76 61 37.9 53 27 80 43 
3. BACKGROUND 
RETINOPATHY 
6 24 34 21.1 22 18 40 21.5 
4. PROLIFERATIVE 
RETINOPATHY 
0 0 11 6.8 7 4 11 5.9 
5. TOTAL 
RETINOPATHY 
6 24 45 27.9 29 22 51  27.4 
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  TABLE 9.  RELATION OF TYPE OF DIABETES, SEX, RETINOPATHY TO   
                    GFR 
 
 
 
 
 
 
 
 
 
 
 
 
  
     BR-BACK GROUND RETINOPATHY 
     PR- PROLIFERATIVE RETINOPATHY 
 
39 patients with type2 DM  had retinopathy whose GFR were less than 60ml/min while 
only 6 patients with type 1 DM  patients with retinopathy had GFR < 60 ml/min.(table 9) 
  
       TYPE 1DM 
 RETINOPATHY    IN  
RELATION TO  GFR          
     TYPE 2DM  
  RETINOPATHY  IN 
RELATION TO GFR 
 
 >90 60-89 30-59 >90 60-89 30-59 
BR 0 0 2 0 2 18 MALE 
PR 0 0 4 0 1 13 
BR 0 0 0 0 1 6 FEMALE 
PR 0 0 0 1 1 2 
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                 TABLE 10  GRADING OF BLOOD PRESSURE IN STUDY GROUP 
 
 
 
 
 
 
 
 
 
 
             
    
 
 
 The prevalence of hypertension in the study population was 56.4%, in which  males  
 contributed 38.7%  and females about 17.7%  combining both groups. In both the groups  
more than 50% had hypertension and most of fell under the category of  stage 1.  
15% of males and  4% of females had isolated systolic hypertension( table 10) 
 
 
 
 
    
MALE FEMALE   TYPE 1 DM    TYPE2 DM
 
 
 BLOOD 
PRESSURE 
NO. % NO % NO % NO % 
1. Normal  BP 13 11.7 16 21.3  5 20 24 14.9 
2. 130-139 / 85-89 26 23.4 16 34.6 7 28 45 27.9 
3. 140-150 / 90-99 34 30.6 27 36 12 48 49 30.4 
4. 160-179 /100-109 16 14.4 1 1.3 1 4 16 9.9 
5. >180  /   >110 5 4.5 2 2.7 0 0 7 4.3 
6. >140   /  < 90 
Isolated systolic 
 hypertension 
17 15.3 3 4 0 0 20 12.4 
7. Total 
Hypertensive 
patients 
72 64.8 33 44 13 52 92 57.1 
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TABLE.11 GFR OF STUDY GROUP WITH REFERENCE TO STAGES 
                                OF CHRONIC KIDNEY DISEASE 
 
 
 
 
 
 
 
 
 
 
 
   
               GFR- GLOMERULAR FILTERATION RATE 
              MDRD- MODIFIED DIET AND RENAL DISEASE 
              DM- DIABETES MELLITUS 
 
. In our study under type 1 DM category 12% under stage 2 CKD  comprised  8 % of  
males and  4%  of  females .Out of  48% under stage 3 of CKD 28% were males  and 
20% were   females respectively in absence of microalbuminuria.  
Similarly  under type 2 DM category 22.9% under stage 2 CKD  comprised  11.8 % of  
males and  11.1%  of  females .Out of  59.6% under stage 3 of CKD 36% were males  
and 23.6% were  females respectively in absence of microalbuminuria( table 11) 
 
 
 
TYPE 1  DM TYPE 2 DM 
 
 
NO. % NO. % 
S.NO GFR 
ml/min 
M F M F M F M F 
1. > 90 5 5 20 20 20 8 12.4 4.9 
2. 60—89 2 1 8 4 19 18 11.8 11.1 
3. 30--59 7 5 28 20 58 38 36 23.6 
4. 15--29 -- -- -- --- --- --- --- --- 
5. < 15 --- --- --- --- --- --- --- --- 
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TABLE 12.  BLOOD PREEURE AND ITS RELATION TO RETINOPATHY AND     
                    GFR 
 
 
 
 BR- BACKGROUND RETINOPATHY 
PR- PROLIFERATIVE RETINOPATHY 
GFR- GLOMERULAR FILTERATION RATE 
MDRD- MODIFIED DIET AND RENAL DISEASE 
 
RETINOPATHY        GFR  BY  MDRD 
BR PR >90 60--89 30--59 
 
 BLOOD 
PRESSURE 
No % No % No % No % No % 
1. Normal  BP 8 15.7 3 5.9 6 15.7 8 20 15 13.8 
2. 130-139 / 85-89 9 17.6 3 5.9 13 34.2 13 32.5 26 24 
3. 140-150 / 90-99 16 31.3 5 9.8 9 23.6 10 25 42 38.8 
4. 160-179 /100-109 1 1.9 0 0 2 5.26 7 17.5 8 7.4 
5. >180  /   >110 2 3.9 0 0 0 0 0 0 7 6.4 
6. >140   /  < 90 
Isolated systolic 
hypertension 
4 7.8 0 0 8 21 2 5 10 9.26 
7. Cumulative 
Percentage in 
category 
40 78.4 11 21.6 38 20.4 40 21.5 108 58 
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 FIGURE- 17 RELATIONSHIP  OF HYPERTENSION TO STAGE OF  CHRONIC  
                                KIDNEY  DISEASE 
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                       FIGURE 18 –RELATIONSHIP OF RETINOPATHY TO STAGE OF CHRONIC  
                                          KIDNEY DISEASE 
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The relation between blood pressure to GFR  and  retinopathy  was analysed . Of total 51 
patients who had retinopathy 78.4% had background retinopathy and 21.6% patients  had 
proliferative retinopathy  . 17.6 % of patients with background retinopathy 5.9% patients 
fell under  the category of stage 1 hypertension  . 31.3%  of patients  with background 
retinopathy and  9.8% patients with proliferative retinopathy  were in stage 2 category of 
hypertension. . less than 4% with retinopathy were in stage 3 and 4 of hypertension. 
There was a  significant  correlation  when analysed with pearson’s statistical correlation 
method. ( p value = 0.159).( table 18) 
 
32.5% under CKD stage 2 and 24% of  stage  3 CKD  was  under  stage 1 hypertension.   
and 25 and 38.8 percent  patients  in stage 2  and stage 3CKD came under stage 2  
hypertension . 17.5 and 7.4  percent of patients in satge 2 and stage 3 CKD  fell under   
stage 3 hypertension.( table 18) 
The relation of GFR calculated by MDRD formula and blood pressure was analysed  
using the same statistical method and significant correlation was found. 
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DISCUSSION AND COMPARATIVE ANALYSIS: 
Long-standing type 1 diabetic patients with normal albumin excretion  rate  are still at  
risk of developing clinically significant nephropathy . It is therefore important to identify 
 markers of increased nephropathy risk among these patients. One possibility is to  
perform kidney biopsies in such patients, given that those with more advanced  
glomerulopathy are more likely to develop abnormalities in albumin excretion rate .  
However, this is not very practical in most clinical settings. So the study was conducted   
whether reduced GFR can be predictive of more advanced underlying glomerular lesions. 
In the present study out of 406 patients which included both type1 DM and type 2 DM  
18% had macro-albuminuria and  14% had microalbuminuria and 45% had normo 
albuminuria. 
 Among normoalbuminuria under type 1 DM category 12% under stage 2 CKD             
    ( GFR -60-89ml/min)  comprised  8 % of  males and  4%  of  females .Out of  48%  
under stage 3 of CKD ( GFR- 30—59ml/min) 28% were males  and 20% were   females  
respectively in absence of albuminuria.  
Similarly  under type 2 DM category 22.9% under stage 2 CKD ( GFR -60-89ml/min)  
comprised  11.8 % of  males and  11.1%  of  females .Out of  59.6% under stage 3 of  
CKD ( GFR- 30—59ml/min) 36% were males  and 23.6% were  females respectively in  
absence of albuminuria 
 
       .In the third NHANES survey, Kramer et al. total of 1180 adults with previously  
diagnosed type 2 DM were included in the study  Among the adults with previously  
diagnosed type 2 DM, the mean reported duration of DM was 9.1 years, and 25% and  
51% reported the use of insulin and diabetes pills, respectively.  
In the present study 23% were recently diagnosed and 20% and 10% with the duration of  
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illness for 6-10 years and 11-15 years in type 2 DM category.. Only 64.2% (n=45) of type 
 2 DM were on regular treatment. All type 1 DM were on regular insulin treatment. 
  Albuminuria (spot urine albumin/creatinine ratio) were absent in 30% of elderly type 2  
diabetic patients with GFR <60 ml/min per 1.73 m2  (Modification of Diet in Renal  
Disease [MDRD] formula) . Adults with type 2 DM and CKD were more likely to have  
macroalbuminuria (19% ), microalbuminuria (45% ), and diabetic retinopathy (28% ). 
In the present study   which included both type1 DM and type 2 DM  18% had macro- 
albuminuria and  14% had microalbuminuria and 45% had normo albuminuria. 
Among all adults with type 2 DM (previously diagnosed and newly diagnosed by ADA  
criteria) with macroalbuminuria (population estimate, 0.5 million), 31% (n = 56) had  
diabetic retinopathy (population estimate, 0.2 million). Among individuals with  
microalbuminuria (population estimate, 3.0 million), 21% (n = 107; population estimate,  
0.6 million) had diabetic retinopathy. Thirteen percent (n = 84; population estimate, 0.6  
million) with diabetic retinopathy did not have microalbuminuria or macroalbuminuria. 
   In the present study 27.4% (n=51) with diabetic retinopathy did not have  
microalbuminuria or macroalbuminuria 
Study conducted by  M. Luiza Caramori, Paola Fioretto, and Michael Mauer  in   
105 patients (65 women) were studied. Age was 35.4 ± 9.1 years, age at diabetes onset 
12.6 ± 7.2 years, and diabetes duration 22.7 ± 9.3 years.  
In the present study the duration of illness was more than 10 years in  type 1 DM . under 
type 2 DM 23% were recently diagnosed and 20% and 10% with the duration of illness 
for 6-10 years and 11-15 years. 75 patients were women as opposed to  111 men. 
Retinopathy was present in 67 patients (64%); 25 (24%) had proliferative changes.  
In the present study out  total 51 patients who had retinopathy 78.4% had background 
retinopathy and 21.6% patients  had proliferative retinopathy. 
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Hypertension was present in 38 (36%) patients; Altogether, 23 (22%) patients were in the 
low and 82 (78%) patients were in the normal GFR groups. There were more women in 
the low GFR than in the normal GFR group . The prevalence of hypertension was the 
same in both groups ; however, when defined as blood pressure values ≥140/90 mmHg or 
use of antihypertensive drugs, the prevalence was greater in the low GFR group .  
The prevalence of hypertension in the present  study  was 56.4%, in which  males  
contributed 38.7%  and females about 17.7%  combining both groups. In both the groups 
more than 50% had hypertension and most of fell under the category of  stage 1 
hypertension. 39 % (n=74)  of  hypertensive  patients were in low GFR group while 10%   
( n=19) hypertensives were in normal GFR group. 
15% of males and  4% of females had isolated systolic hypertension 
The prevalence of any retinopathy was more frequent in low versus normal GFR patients 
, as was proliferative retinopathy .(ref :32)  
In the present study out  total 51 patients who had retinopathy 78.4% had background 
retinopathy and 21.6% patients  had proliferative retinopathy and retinopathy was more 
frequent in low GFR ( GFR= <  90 ml/min) group(26.8%). 
  
PH Lane, MW Steffes and SM Mauer and colleagues reported eight women with type 1 
DM  with low creatinine clearance rate (CCR) and normal urinary albumin excretion. 
(ref: 27) 
In the present study (n=15/25 ) 60%of  type 1 DM had low GFR. Females contributed  
24% with low GFR. 
Caroline K. Kramer and colleagues in their study reported out of  total  660 
normoalbuminuric type 2 diabetic patients were evaluated, Eighty-four (12.7%) had low 
GFR (15–60 ml/min per 1.73 m2), and the remaining 576 comprised the reference group 
(87.2%) .The group of patients with low GFR was older (62.9 ± 10.3 vs. 56.8 ± 9.5 
years), had more women (77.4 vs. 60.2% ).  
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In the present study of 406 patients which included both type1 DM and type 2 DM   45% 
had normo albuminuria. 60% under type 1 DM and  82.5% under type 2 DM  
had  CKD   ( GFR  <  90 ml/min). 58% under stage 3 ( GFR= 30—59ml/min). Regarding 
sex  involvement  males out numbered  females {  46%  (n=86)  vs  33% ( n=46.2)  }. 
CKD  also occurred more frequently  after 60 years  { 55.3%  (n=103)  } 
The prevalence of micro- and macrovascular diabetes complications  in  low  GFR group 
was    (diabetic retinopathy: 28.4%  P = 0.037; coronary heart disease: 29.2%   P = 0.729; 
peripheral vascular disease: 33.3 %, P = 0.089; and cerebrovascular disease: 7.7%                  
P = 0.218)      ( ref: 29) 
.  In the present study  diabetic complication in low GFR group was(diabetic retinopathy: 
26.8%  P = 0.575; coronary heart disease: 17.2%   P = 0.331; peripheral vascular disease: 
12.3 %, P = 0.331; and cerebrovascular disease: 4.8%  P = 0.019)   
 Study conducted  by Richard J. MacIsaac and colleagues revealed in about  109 patients 
(36%) had a GFR <60 ml · min-1 · 1.73 m-2. The overall prevalence of normo-, micro-, and 
macroalbuminuria was 43 of 109 (39%), 38 of 109 (35%), and 28 of 109 (26%), 
respectively. Compared with patients with macroalbuminuria, those with 
normoalbuminuria were more likely to be older and female.  
In the present study out of 406 patients which included both type1 DM and type 2 DM  
18% had macro-albuminuria and  14% had microalbuminuria and 45% had normo 
albuminuria. 
 Males were predominatly affected than females . Older individuals were commonly 
affected as seen in Richard J. MacIsaac and colleagues study. (ref:28) 
 In several independent local surveys it was found that 15 to 20% of type 2 diabetic 
patients reaching end-stage renal failure lacked major proteinuria and had shrunken 
kidneys, raising the unproven assumption of ischemic nephropathy. 
Vincent Rigalleau et al  in their study of  89 patients with diabetes and a modification of 
diet in renal disease (MDRD) estimated GFR (e-GFR) <60 ml/min per 1.73 m2 underwent 
a 51Cr-EDTA B-isotopic GFR determination and were followed up for 38 ± 11 months. 
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The mean MDRD e-GFR (41.3 ± 13.1 ml/min per 1.73 m2) did not significantly differ 
from the i-GFR (45.6 ± 29.7). Of the subjects, 15 (17%) were normoalbuminuric. Their i-
GFR did not differ from the albuminuric rate and from their MDRD e-GFR, although 
their serum creatinine was lower (122 ± 27 vs. 160 ± 71 µmol/l, P < 0.05): 71% would 
not have been detected by measuring serum creatinine (sCr) alone. They were less 
affected by diabetic retinopathy.(P < 0.05 vs. albuminuric).( ref:31)  
In the present study out of 406 patients which included both type1 DM and type 2 DM  
18% had macro-albuminuria and  14% had microalbuminuria and 45% had normo 
albuminuria. In the present study out  total 51 patients who had retinopathy 78.4% had 
background retinopathy and 21.6% patients  had proliferative retinopathy in the absence 
of albuminuria. 
 
SUMMARY: 
          From the study ANALYSIS OF  GFR  IN  NON-ALBUMINURIC  TYPE-1  AND  TYPE-2  
DIABETES MELLITUS  IN  EARLY  DETECTION   OF CHRONIC  KIDNEY  DISEASE - CROSS-
SECTIONAL STUDY conducted in Govt. Madurai Rajaji Hospital  in Department  of 
Medicine and Department of diabetology in186 patients , it was found  that  both type 1( 
n=15/25) and type 2 (n=133/161)  diabetic patients had nephropathy in the absence of 
significant urinary albumin. 
1.      Out of 186  patients 161 were categorized to Type2 DM and  25  to Type 1 DM.    
        Among male 14( 13%) were type 1 DM and 97 (87%) were type 2 DM .  11 (14%)  
        females fall under the category of type 1 DM and  64 (86% ) in type 2 DM. 
2.      Among  Type 1 DM  14  (64%) patients had duration of diabetes for 11—15 years. 
        In type 2 DM  66( 41.2 % ) patients  was recently diagnosed. 
3.      Among normoalbuminuria under type 1 DM category 12% under stage 2 CKD             
      ( GFR -60-89ml/min)  comprised  8 % of  males and  4%  of  females .Out of  48%  
       under stage 3 of CKD ( GFR- 30—59ml/min) 28% were males  and 20% were 
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       females respectively in absence of albuminuria.  
       Similarly  under type 2 DM category 22.9% under stage 2 CKD ( GFR -60- 
       89ml/min) comprised  11.8 % of  males and  11.1%  of  females .Out of  59.6%    
      under stage 3 of   CKD ( GFR- 30—59ml/min) 36% were males  and 23.6% were  
      females respectively in  absence of albuminuria 
4.   In the present study   which included both type1 DM and type 2 DM  18% had macro- 
     albuminuria and  14% had microalbuminuria and 45% had normo albuminuria. 
5.   In the present study out  total 51 patients who had retinopathy 78.4% had background   
      retinopathy and 21.6% patients  had proliferative retinopathy in the absence of  
        albuminuria. 
6.   The prevalence of hypertension in the present  study  was 56.4%, in which  males    
     contributed 38.7%  and females about 17.7%  combining both groups. 39 % (n=74)  of   
     hypertensive  patients were in low GFR group while 10%   ( n=19) hypertensives were  
     in normal GFR group. 
 
7. .  In the present study  diabetic complication in low GFR group was(diabetic 
           retinopathy: 26.8%  P = 0.575; coronary heart disease: 17.2%   P = 0.331; peripheral  
      vascular disease: 12.3 %, P = 0.331; and cerebrovascular disease: 4.8%  P = 0.019)  
 
 Alternatively the kidney may be the victim of extrarenal factors such as a history of  
hypertension, malnutrition, or cholesterol microembolism, to mention only a few. It will  
be particularly relevant to address the above potential non classical pathogenetic  
pathways  if it were  ever to arrive at specific targeted interventions for this segment of  
the diabetes population. Lurbe et al. (ref:25) recently reported that nighttime 
ambulatory blood pressure values and “nondipper” status were significant predictors of  
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progression from normoalbuminuria to microalbuminuria in adolescent patients 
with type 1 diabetes. Unfortunately   night time ambulatory blood pressure monitoring   
was not possible  due non availability of  measuring device,.but a  6  times blood  
pressure recording was done to minimize  the errors 
Parving et al stated that the absence of retinopathy greatly reduced the likelihood that 
albuminuria was due to diabetic glomerulosclerosis in type 1 or type 2 DM. In the 
absence of retinopathy or albuminuria  in 30% of adults with a GFR less than 60 mL/min 
per 1.73 m2 BSA, classic diabetic glomerulosclerosis is unlikely to be the underlying 
renal pathology 
 
 
 
CONCLUSION: 
In conclusion, more than 50%  adults 40 years of age or older with type 2 DM and patient 
with type 1 DM for more than period of 10 years  had CKD either in stage 1 or stage 2. 
  36%( n=9/25) of males and  24%( n=6/25) of females had low GFR ( GFR=< 90 
ml/min) under type 1 DM. Similarly in type 2 DM( n=77/161) 47.8% males and               
( n=56/161)   34.7% females had decreased  GFR in absence of  albuminuria. 
25% with CKD were  less than 50years and 55.3% were more than 50years old. 
16% of females  and 8% males with retinopathy had low GFR in type 1 DM group.. 
While 16.7% males  and 11.1% females  with retinopathy had low GFR in type 2 DM 
group. 
 
1.. The results suggest that serum creatinine levels should  be measured and GFR to  be 
estimated  in  all  diabetic individuals who are at risk of developing nephropathy  in 
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addition to monitoring urine albumin excretion and funduscopic changes to screen for 
kidney disease. 
2. Because it would not be practical to perform renal biopsies in all normoalbuminuric 
patients, it is  recommended  that long-standing normoalbuminuric  diabetic  patients with 
retinopathy or hypertension should have GFR measured on a regular basis. 
3. Since the night time ambulatory blood pressure values and “nondipper” status were 
significant predictors of  progression from normoalbuminuria to microalbuminuria in 
diabetic patients night time monitoring of blood pressure should be done in those who are 
at risk of developing diabetic nephropathy 
4.The mean MDRD estimated GFR did not significantly differ from the isotope  
estimated-GFR . So GFR  estimation can be  safely relayed with MDRD formula. 
 ( ref:31) 
 
 
LIMITATION OF STUDY 
1. The results were predominantly obtained from a cross-sectional survey of patients 
2. The sample size in type 1 DM category was small. 
3. Night time ambulatory blood pressure could not be recorded. 
4. Retinopathy could not be assessed in significant number of patients since they had 
cataract. 
5. Patients recruited  here may not be representative of the entire population. 
6. Renal biopsy was not done which might have strengthened  findings of the study. 
7. GFR estimation with inulin or iodothalamate  might have improved validity  
of GFR estimated  with MDRD formula. 
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                                                         PROFORMA  
   
 
 
        NAME:                                                        AGE:                                SEX: 
 
       ADDRESS:                                                 OP/IP NO:   
 
 
       OCCUPATION: 
 
 
       TYPE  OF  DIABETE MELLITUS                      TYPE  1  /  TYPE  2 
 
 
        
      DURATION    OF  DISEASE 
 
 
      TREATMENT  DETAILS                           REGULAR   /   IRREGULAR   /    
  
                                                                    NEWLY DIAGNOSED / NO TREATMENT 
 
                                                                      
 
 
                         SYMPTOMS: 
                            
                             POLYURIA, POLYDISIA, POLYPHAGIA 
 
                            WEIGHT LOSS 
  
                            CHEST PAIN , PALPITATION,  BREATHLESSNESS 
 
          LOWER LIMB  SWELLING,  FACIAL PUFFINESS 
          DYSURIA, OLIGURIA, HEMATURIA  
         PRURITUS VULVA  PINS & NEEDLE , BURNING  SENSATION  IN EXTREMITES 
         FOOT INFECTION  /   H/O   AMPUTATION / DIABETIC  FOOT 
         DIMINISION OF  VISION 
        ACUTE COMPLICATIONS  IF  ANY 
        ABSENT SWEATING, POSTURAL GIDDINESS, DIARRHEA 
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PAST  HISTORY 
                        CAD 
                        HYPERTENSION 
                        PERIPHERAL  VASCULAR  DISEASE 
                        SMOKING 
                       ALCOHOL 
                       ACEI  MEDICATION 
EXAMINATION 
 HEIGHT(cm)           WEIGHT(kg)       BMI                WAIST  CIRCUMFERENCE(cm) 
 
 
PULSE 
PERIPHERAL   PULSES 
 
BLOOD PRESSURE 
(mean  of  6  readings) 
 
POSTURAL DROP OF BP            
 
       
 
RETINAL EXAMINATION: 
GRADING  
1. NORMAL FUNDUS  
2. BACKGROUND RETINOPATHY 
3. PROLIFERATIVE RETINOPATHY 
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BLOOD Hb   in  gm%: 
 
URINE                                     SUGAR:            ALBUMIN :           DEPOSITS: 
 
BLOOD  SUGAR :                     
 
BLOOD  UREA: 
 
SERUM  CREATININE: 
 
LIPID  PROFILE :             LDL      VLDL       HDL      TGL         CHOLESTROL 
 
  
 
 
 
URINE  SPOT  PROTEIN   CREATININE  RATIO     
  
 
 
24 HRS  URINARY 
PROTIEN                              1st SAMPLE       2nd SAMPLE            3rd SAMPLE 
 
Mgs/day  
 
 
 
EQUATION  FROM  MODIFICATION  OF  DIET  IN  RENAL  DISEASE  STUDY 
 
                                                            2                                              --1.154                 -- 0 .203            
      ESTIMATED  GFR (ml/min per 1.73m^ )      =    1.86     *    ( Pcr)^        *          (age) ^   
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S.NO NAME AGE SEX
TYPE  OF  
DIABETES 
DURATION 
OF 
ILLNESS  
IN YEARS  
1 PONNUKALAI 1 1 2 0 2
2 PANDI 64 1 2 0 2
3 MAYAKKAL 48 2 2 0 2
4 NAGARANI 40 2 2 7 1
5 OTCHAMMAL 55 2 2 0 2
6 RATHINAM 60 1 2 4 0
7 ARUMUGAM 65 2 2 4 1
8 KAMATCHI 58 1 2 0 2
9 RAKKAN 62 1 2 5 0
10 PANDI 46 1 2 0 2
11 GURUSAMY 54 1 2 5 0
12 MALAISAMY 65 1 2 20 0
13 BOOMIRAJA 50 1 2 10 0
14 SAMSUDEEN 52 1 2 0 2
15 MATHIVALAN 55 1 2 0 2
16 CHINNARAJA 40 1 2 0 2
17 KRISHNAMOORTHY 71 1 2 20 0
18 GURUNATHAN 58 1 2 15 0
19 RAMAMOORTHY 63 1 2 10 0
20 SAVIOUR 68 1 2 20 0
21 JAYABAL 37 1 2 0 2
22 ANGUSAMY 75 1 2 25 0
23 SIVAKUMAR 48 1 2 5 0
24 LAKSHMAN 72 1 2 0 2
25 RAASHEETH 53 1 2 0 2
26 SELVARAJ 54 1 2 0 2
27 RAJAMOHAN 49 1 2 3 1
28 KARUPPUSAMY 47 1 2 2 1
29 PITCHAI 60 1 2 5 1
30 RENGAIAH 68 1 2 10 0
31 MARUTHAMUTHUPILLAI 40 1 2 10 0
32 KRISHNAN 64 1 2 12 0
33 AYYANAR 40 1 2 0 2
34 MANI 47 1 2 0 2
35 VARGHESE 50 1 2 3 1
36 MADASAMY 70 1 2 5 1
37 MUTHUKRISHNAN 50 1 2 7 0
38 MURUGANATHANAN 60 1 2 4 1
39 PANDI 68 1 2 7 1
40 PARAMASIVAM 47 1 2 0 2
41 MURUGESAN 56 1 2 3 1
42 SEKAR 60 1 2 0 2
43 ABDUL SALEEM 75 1 2 23 1
44 RAMASAMY THEVAR 85 1 2 34 0
45 SENTHIL 48 1 2 0 2
46 SINGARAM 60 1 2 10 1
47 SAMUEL 80 1 2 13 0
48 NATARAJAN 45 1 2 15 1
49 MEENAKHSHI 55 1 2 7 0
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SUNDARAM
50 RAJENDERAN 45 1 2 0 2
51 PARAMASIVAM 50 1 2 4 1
52 PALANISAMY 50 1 2 10 0
53 BABU 56 1 2 0 2
54 MUTHAIAH 65 1 2 12 0
55 BATCHA 60 1 2 8 0
56 RAMAKRISHNAN 67 1 2 15 0
57 AJMALKHAN 55 1 2 9 0
58 MAYANDI 72 1 2 5 1
59 RENGASAMY 55 1 2 0 2
60 VEERANAN 70 1 2 13 0
61 VEERAMANI 47 1 2 0 2
62 KAMARDEEN 60 1 2 0 2
63 ABDUL MAJEED 55 1 2 4 1
64 GOPAL MOORTHY 57 1 2 10 0
65 CHINNAIH 50 1 2 3 1
66 KAMARDEEN 60 1 2 6 1
67 RASUTHEVAR 72 1 2 14 0
68 NAGAPPAN 58 1 2 6 0
69 PALANI 55 1 2 0 2
70 ARUMUGAM 40 1 2 0 2
71 PURUSHOTHAMAN 70 1 2 12 0
72 KANNAN 43 1 2 0 2
73 THANGAVELU 69 1 2 20 0
74 SHEIK MOHAMMED 66 1 2 0 0
75 SAMSUDEEN 52 1 2 0 2
76 DHARMARAJ 52 1 2 0 2
77 ANTHONY 67 1 2 8 1
78 AYYASAMY 62 1 2 5 1
79 JALEEM 56 1 2 0 2
80 RAMAR 40 1 2 0 2
81 RAMASAMY 70 1 2 15 0
82 THIRUNAVUKU ARASU 42 1 2 0 2
83 PANDI 60 1 2 5 1
84 THANGARAJAN 65 1 2 12 0
85 MARUTHAMUTHUPILLAI 60 1 2 5 1
86 JAYARAMAM 40 1 2 0 2
87 APAAVU 62 1 2 8 1
88 SEKAR 52 1 2 0 2
89 KRISHNAN 60 1 2 7 1
90 GURUSAMY 68 1 2 12 0
91 JEYARAJ 65 1 2 15 0
92 ULAGANATHAN 48 1 2 0 2
93 SETHUPANDI 55 1 2 0 2
94 MUTHUSELVAM 40 1 2 0 2
95 MARIAPPAN 40 1 2 0 2
96 KILAVAPPAN 65 1 2 14 0
97 KARUPPUSAMY 45 1 2 5 1
98 RAMAKRISHNAN 70 1 2 15 0
99 KARUPPANAN 60 1 2 10 0
100 PANDI 73 1 2 0 2
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101 MANI 55 1 2 6 1
102 CHINNAMMAL 55 2 2 0 2
103 SARASWATHI 65 2 2 0 2
104 PITCHAIAMMAL 45 2 2 0 2
105 LOGAMMAL 55 2 2 2 1
106 SUNDARAMMAL 60 2 2 0 1
107 JEGATHAMBAL 62 2 2 0 1
108 MUTHULAKSHMI 65 2 2 0 2
109 PUSPAM 65 2 2 4 1
110 KRISHNAVENI 50 2 2 0 2
111 SUGANTHI 67 2 2 0 2
112 LAKSHMI 40 2 2 0 2
113 MARY 55 2 2 5 1
114 MANONMANI 55 2 2 0 2
115 PALANIAMMAL 50 2 2 0 2
116 KAMATCHI 45 2 2 0 2
117 GOMATHI 61 2 2 8 1
118 ANNAPOORANI 59 2 2 7 0
119 POTTAMMAL 55 2 2 2 1
120 VELAMMAL 52 2 2 0 2
121 RADHA 65 2 2 7 0
122 VANAJA 58 2 2 4 1
123 VEERAMMAL 45 2 2 0 2
124 MUNIAMMAL 70 2 2 0 0
125 CHELLAMMAL 48 2 2 6 0
126 ESAKIAMMAL 65 2 2 8 0
127 REGINA 50 2 2 0 2
128 DHANALAKSHMI 67 2 2 3 1
129 MATHI 60 2 2 2 0
130 RAMUTHAI 65 2 2 5 1
131 RAJALAKSHMI 50 2 2 0 2
132 SUNDARAVALLI 62 2 2 5 1
133 PETCHI 60 2 2 6 0
134 NAGARATHINAM 58 2 2 5 0
135 PANAIAMMAL 65 2 2 0 2
136 KURUVAMMAL 50 2 2 0 2
137 JEYAMANI 48 2 2 0 2
138 MEENAKSHI 60 2 2 6 1
139 VELLAIAMMAL 56 2 2 4 1
140 SUNDARI 55 2 2 0 2
141 MUTHU 42 2 2 0 2
142 SUMITHRA 65 2 2 0 2
143 THANGAVELU 55 2 2 5 1
144 SUNDARI 56 2 2 4 0
145 MALAR 56 2 2 0 2
146 MAHALIHAMMAL 65 2 2 10 0
147 AMIRTHAM 65 2 2 5 1
148 SUNDARI 57 2 2 7 0
149 NATCHAMMAL 60 2 2 13 1
150 MARIA PUSPAM 70 2 2 15 0
151 PACKIAYAM 50 2 2 2 1
152 PALANIAMMAL 48 2 2 7 0
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153 IRULAYEE 60 2 2 10 0
154 THANGAM 72 2 2 15 0
155 RATHINA VELU 65 2 2 0 2
156 CHANDRA 55 2 2 0 2
157 SANTHANAM 65 2 2 3 1
158 LOGAMBAL 70 2 2 20 0
159 VELLAIAMMAL 55 2 2 5 0
160 FATIMA MARY 53 2 2 0 2
161 AVUDAIAMMAL 60 2 2 6 1
162 MUTHUPANDI 23 1 1 12 1
163 SATISH BABU 29 1 1 10 1
164 MURUGAN 21 1 1 10 1
165 KALAIPPAN 30 1 1 15 1
166 MURUGESAN 39 1 1 20 1
167 RAMAR 57 1 1 35 1
168 ANTHONY 27 1 1 13 1
169 RAJU 35 1 1 20 1
170 SARAVANAN 34 1 1 22 1
171 ARUMUGAM 32 1 1 16 1
172 RAMANATHAN 32 1 1 15 1
173 MURUGESAN 34 1 1 15 1
174 BALAMURUGAN 28 1 1 12 1
175 PANDIARAJAN 33 1 1 15 1
176 THANGAM 30 2 1 13 1
177 KARUPPANNAN 27 2 1 13 1
178 MAYILVAHANNAN 40 2 1 24 1
179 MALAR VIZIHI 24 2 1 10 1
180 AMEENA BEEVI 22 2 1 10 1
181 DHANALAKSHMI 20 2 1 10 1
182 LAKHSMI 30 2 1 16 1
183 ALAGI 48 2 1 25 1
184 MALAR 25 2 1 10 1
185 JEYASEELA 38 2 1 22 1
186 INDIRANI 28 2 1 10 1
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CHEST PAIN 
PALPITATION 
BREATHLESSNES
S 
POLYURIA 
POLYPHAGIA 
POLYDIPSIA
WEIGH
T LOSS
PEDAL 
OEDEMA
PRURITI
S VULVA
DIABETI
C FOOT  
DIMINISIO
N OF 
VISION
1 1 2 2 0 2 2
1 1 2 2 0 2 1
1 1 1 2 1 2 1
2 2 1 2 1 2 2
2 1 2 2 0 2 1
1 2 2 2 0 2 2
2 2 2 2 0 2 0
2 2 2 2 0 2 2
1 2 2 2 0 2 0
1 1 1 2 0 2 2
2 2 2 2 0 2 2
1 2 1 1 0 1 0
1 2 2 2 0 2 2
1 2 2 2 0 2 2
2 2 2 2 0 2 2
1 1 2 2 0 2 2
2 2 1 1 0 1 0
2 2 2 2 0 2 2
1 2 2 2 0 2 0
1 2 1 1 0 2 0
1 1 2 2 0 2 2
1 2 1 1 0 1 0
1 2 2 2 0 2 2
1 2 1 1 0 2 0
2 2 2 1 0 2 2
1 2 2 2 0 2 2
1 2 2 2 0 2 1
2 2 2 2 0 2 2
2 2 2 2 0 2 2
1 2 1 1 0 2 0
2 2 2 2 0 2 2
2 2 2 2 0 2 2
2 1 1 2 0 2 2
1 2 2 2 0 2 2
2 2 2 2 0 2 2
2 2 2 2 0 2 0
1 2 2 2 0 2 1
2 2 2 2 0 2 2
2 2 1 2 0 1 0
2 2 2 2 0 2 2
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1 2 2 2 0 2 2
2 2 2 2 0 2 2
2 2 1 1 0 1 0
1 2 1 1 0 1 0
2 1 2 2 0 2 2
2 2 2 2 0 2 2
2 2 1 1 0 1 0
2 1 2 2 0 1 2
2 2 2 2 0 2 2
2 1 2 2 0 2 2
1 2 2 1 0 2 2
2 2 2 1 0 2 2
2 2 2 2 0 2 2
2 2 2 2 0 1 0
1 2 2 2 0 2 2
2 2 1 1 0 1 0
2 2 2 2 0 2 2
2 2 1 2 0 2 0
2 2 2 2 0 2 2
2 2 1 1 0 1 0
2 1 2 2 0 2 2
2 2 2 2 0 2 0
2 2 2 2 0 2 1
2 2 2 1 0 1 2
2 2 2 2 0 2 2
2 2 2 2 0 2 2
2 2 1 1 0 1 0
2 2 2 2 0 2 2
1 2 2 1 0 2 2
2 1 2 2 0 2 2
2 2 1 2 0 1 0
1 1 2 2 0 2 2
2 2 1 1 0 1 0
2 2 2 1 0 2 0
1 2 2 2 0 2 2
2 2 2 2 0 2 2
1 2 1 1 0 2 0
1 2 2 2 0 2 2
2 2 2 2 0 2 2
1 1 2 2 0 2 2
1 2 1 1 0 1 0
1 1 2 2 0 2 2
2 2 2 2 0 2 0
2 2 2 2 0 2 0
1 2 2 2 0 2 0
1 1 2 2 0 2 2
1 2 2 2 0 2 0
2 2 2 2 0 2 1
1 2 2 2 0 2 2
2 2 1 2 0 2 0
2 2 2 2 0 1 1
2 2 2 2 0 2 2
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2 2 2 2 0 2 2
1 1 2 2 0 2 2
2 1 2 2 0 2 2
2 2 1 1 0 2 0
1 2 2 2 0 2 2
1 2 1 1 0 2 0
1 2 2 2 0 1 2
2 2 1 2 0 2 0
2 2 2 2 0 2 2
1 2 2 2 2 2 2
2 2 2 2 2 2 0
1 1 1 2 2 2 2
1 2 2 2 1 2 2
2 2 2 2 2 2 0
1 2 2 2 2 2 0
1 2 1 2 2 2 0
2 2 2 2 1 2 0
2 2 2 2 2 2 2
2 2 2 2 2 2 0
1 1 1 2 1 2 2
2 2 2 2 2 2 2
2 2 2 2 2 2 2
2 2 2 2 1 2 2
2 1 2 2 2 2 2
2 2 2 2 2 2 0
2 2 2 2 2 1 0
2 2 2 2 1 2 2
2 2 2 2 2 2 2
2 2 2 2 2 2 0
1 2 2 2 1 2 2
2 1 2 2 2 2 2
1 2 1 1 2 2 0
1 2 2 2 2 2 2
1 2 1 2 2 2 0
2 2 1 2 1 2 2
1 2 2 2 2 2 0
2 2 2 2 2 2 2
1 2 2 2 2 2 0
1 2 2 2 2 2 2
1 2 2 2 2 2 2
2 2 2 2 1 2 2
2 2 2 2 2 2 0
2 2 2 2 1 2 0
1 2 2 2 2 2 1
2 1 2 2 1 2 2
1 2 2 2 1 2 2
1 2 2 2 2 2 0
2 2 2 2 2 2 2
2 1 2 2 1 2 2
1 2 1 2 1 2 0
2 2 2 2 2 2 2
2 2 2 2 2 2 2
 95
2 2 2 2 2 2 2
2 2 2 1 2 2 0
2 2 2 2 1 2 0
1 2 1 2 2 2 2
2 2 2 1 1 1 2
2 2 1 2 2 1 0
1 2 2 2 2 2 2
2 2 2 2 1 2 2
2 2 2 1 2 2 2
2 2 1 1 2 1 0
1 2 2 2 2 2 0
2 2 2 2 1 2 2
1 2 2 2 1 2 0
2 2 1 1 2 1 0
2 2 2 2 1 2 2
2 2 2 2 2 2 2
1 2 2 2 2 2 0
1 2 2 2 2 2 2
2 2 1 2 0 2 2
2 2 2 2 0 2 2
2 2 2 2 0 2 2
1 2 2 2 0 2 2
1 2 1 2 0 2 2
2 2 2 2 0 2 2
2 2 2 2 0 2 2
2 2 2 2 0 2 2
2 2 2 2 0 2 2
2 2 1 2 0 2 2
2 2 2 2 0 2 2
2 2 2 2 0 2 2
2 2 1 2 0 2 2
2 2 2 2 0 2 2
2 2 2 2 0 2 2
1 2 1 2 2 2 2
2 2 2 2 1 2 2
2 2 2 2 2 2 2
2 2 1 2 1 2 2
2 2 2 2 2 2 2
1 2 2 2 1 2 2
2 2 1 2 1 2 2
1 2 2 2 2 2 2
2 2 2 2 2 2 2
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ACUTE 
COMPLICATION CAD / MI HT PVD SMOKING ALCOHOL PR
BP(mean of 
6 readings)
POSTURAL 
BP DROP
3 2 2 2 2 1 98 4 1
4 2 2 2 2 2 96 2 1
0 2 2 2 2 2 90 0 2
0 2 1 1 2 2 88 1 2
1 2 2 2 2 2 98 1 2
0 1 1 2 2 1 94 0 2
0 1 1 2 2 2 84 2 2
0 1 2 2 1 2 86 3 1
0 1 1 2 1 1 90 2 2
0 2 1 2 2 2 94 2 1
0 2 2 1 2 2 86 1 2
0 1 1 1 1 1 82 2 2
0 1 2 2 1 2 76 1 2
0 1 2 2 1 2 76 0 2
0 2 2 2 2 2 92 1 2
0 1 2 2 2 1 98 2 2
0 2 1 1 2 2 98 3 1
0 2 2 2 2 2 86 2 2
0 1 2 2 1 2 88 5 2
0 1 2 2 1 1 74 0 2
0 1 2 2 1 2 66 0 2
0 1 1 1 1 1 82 3 1
0 1 1 2 1 2 84 4 2
0 1 1 2 1 1 74 5 2
0 2 2 2 2 2 92 2 2
0 1 1 2 1 2 64 5 1
0 1 2 2 1 2 64 1 2
0 2 2 2 2 1 84 5 2
0 2 1 2 2 2 76 5 1
0 1 2 2 1 2 84 2 2
0 2 1 2 2 2 76 3 1
0 2 1 2 2 1 92 5 1
1 2 2 2 2 2 84 1 2
0 1 2 2 2 1 76 0 2
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0 2 2 2 2 2 82 1 2
0 2 2 2 1 2 74 1 2
5 2 2 2 1 1 76 2 1
0 2 2 1 2 2 84 1 2
0 2 2 1 2 2 64 1 2
0 2 2 2 2 2 62 1 2
0 1 2 2 1 2 92 0 2
0 2 1 2 2 1 94 2 2
2 2 2 1 2 2 76 1 2
0 1 2 1 2 2 84 1 2
0 2 2 2 1 1 72 2 2
2 2 2 2 2 2 76 0 2
0 2 1 1 2 2 84 4 1
0 2 1 1 2 2 92 3 1
0 2 1 2 2 2 74 2 2
1 2 2 2 1 2 86 1 2
0 1 1 2 2 2 84 2 2
0 2 2 2 2 2 86 1 2
0 2 2 2 2 2 82 1 2
2 2 2 1 1 2 84 1 2
0 1 2 2 2 2 76 1 2
0 2 2 1 2 2 92 1 2
0 2 2 2 1 2 84 0 2
1 2 2 2 2 2 86 0 2
3 2 2 2 2 2 84 0 2
1 2 2 1 1 2 86 5 2
0 2 2 2 2 2 86 2 2
0 2 2 2 2 1 88 2 2
3 2 1 2 1 2 74 2 1
2 2 2 1 2 2 76 2 1
0 2 2 2 2 2 84 1 2
0 2 2 2 1 2 72 2 1
3 2 2 1 2 2 94 5 2
0 2 2 2 2 2 86 5 1
0 1 1 2 1 2 82 1 2
0 2 2 2 1 2 86 2 2
0 2 2 1 2 1 94 4 1
0 1 2 2 2 2 82 4 1
3 2 1 1 1 2 86 3 1
6 2 1 2 2 2 92 3 1
0 1 2 2 2 2 82 5 1
0 2 2 2 2 2 94 5 1
0 1 1 2 1 2 94 5 1
0 2 1 2 2 2 96 5 2
0 2 2 2 1 2 94 3 1
4 2 2 2 1 1 86 3 2
0 1 2 1 2 2 82 3 1
0 1 2 2 2 2 84 2 2
0 2 1 2 1 2 74 3 1
1 1 2 2 2 2 72 2 2
4 2 2 2 1 2 76 2 2
4 2 2 2 1 1 94 5 1
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4 2 2 2 1 2 76 2 2
0 1 1 2 1 2 74 2 1
4 2 2 2 1 2 76 5 1
3 2 2 2 1 2 74 3 2
0 2 2 1 2 2 92 2 1
0 2 1 2 2 2 96 2 2
0 2 2 2 1 2 84 3 1
0 1 2 2 2 1 76 1 2
1 2 2 2 2 2 94 1 1
0 2 1 2 1 2 76 2 2
4 2 2 2 1 2 84 5 2
0 1 2 2 1 2 94 3 1
0 1 1 1 2 2 76 5 1
0 2 2 2 2 2 92 3 1
3 2 2 2 2 2 84 2 2
0 1 1 2 2 2 76 0 2
0 2 1 2 2 2 84 1 2
5 2 1 2 2 2 84 2 2
5 2 1 2 2 2 86 5 1
0 2 2 2 2 2 82 1 2
0 1 2 2 2 2 86 2 2
4 2 2 2 2 2 84 1 2
0 2 1 2 2 2 82 2 2
0 2 1 2 2 2 84 1 2
0 2 1 2 2 2 74 1 2
0 1 1 2 2 2 76 1 2
2 2 1 2 2 2 82 1 2
6 2 1 2 2 2 84 1 2
0 2 2 2 2 2 82 0 2
2 2 2 2 2 2 88 0 2
2 2 2 2 2 2 86 0 2
0 2 2 1 2 2 84 0 2
0 2 2 2 2 2 82 2 2
0 2 2 2 2 2 84 1 2
0 2 2 2 2 2 86 0 2
0 1 2 2 2 2 84 1 2
0 2 2 2 2 2 82 2 2
0 1 1 2 2 2 86 2 2
3 2 1 2 2 2 88 2 2
0 2 1 2 2 2 88 3 1
0 2 2 2 2 2 74 2 2
0 2 1 2 2 2 76 2 2
0 2 2 2 2 2 76 1 2
0 2 1 2 2 2 72 2 2
0 2 1 2 2 2 74 1 2
5 2 1 2 2 2 64 0 2
3 2 2 2 2 2 68 0 2
1 2 2 2 2 2 64 0 2
0 2 2 2 2 2 98 0 2
0 1 1 2 2 2 100 0 2
0 2 2 2 2 2 68 2 2
4 2 2 2 2 2 76 1 2
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0 1 2 2 2 2 84 1 2
0 2 2 2 2 2 86 1 2
0 2 2 2 2 2 82 0 2
0 2 1 2 2 2 84 2 2
0 2 2 2 2 2 110 2 1
0 2 2 2 2 2 86 2 2
0 2 2 2 2 2 94 0 2
3 2 2 2 2 2 94 2 1
0 2 2 2 2 2 98 1 2
5 2 1 1 2 2 92 1 2
0 2 2 1 2 2 86 1 2
0 2 2 2 2 2 86 2 1
5 2 2 2 2 2 84 1 2
0 2 2 2 2 2 82 1 2
0 2 2 2 2 2 76 5 2
1 2 2 1 2 2 74 4 1
0 1 1 2 2 2 78 4 1
0 1 2 2 2 2 98 2 2
5 1 1 2 2 2 94 2 1
0 2 1 1 2 2 92 2 2
0 2 2 2 2 2 86 2 1
1 2 2 2 2 2 84 1 2
0 1 2 2 2 2 82 5 2
2 2 2 2 2 2 84 3 1
0 2 2 2 2 2 74 2 2
0 2 2 2 2 2 76 1 2
0 2 2 2 2 2 72 1 2
0 2 2 2 2 2 78 2 1
0 2 2 2 1 2 74 2 2
0 2 2 2 2 2 75 2 1
0 2 2 2 1 2 76 1 2
1 2 2 2 2 2 84 2 2
0 2 2 2 1 2 75 2 1
0 2 2 2 2 2 76 1 2
0 2 2 2 1 1 74 0 2
0 2 2 2 2 2 74 0 1
0 2 2 2 1 1 75 0 2
0 2 2 2 2 2 76 1 2
0 2 2 2 2 2 78 2 2
0 2 2 2 2 2 84 1 1
0 2 2 2 2 2 74 1 2
0 2 2 2 2 2 78 0 1
0 2 2 2 2 2 84 0 2
0 2 2 2 2 2 86 2 1
0 2 2 2 2 2 86 2 2
0 2 2 2 2 2 94 2 2
0 2 2 2 2 2 84 2 2
1 2 2 2 2 2 82 2 1
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RETINOPATHYHb  gm % 
BLOOD
SUGAR
BLOOD 
UREA
URINE 
SUGAR
URINE 
ALBUMIN
URINE 
DEPOSITS 
(PUS CELLS) 
24 HRS 
URINARY 
PROTEIN 
(MEAN OF 
3 
SAMPLES)Sr.CHOLESTROL
2 10.5 282 39 2+ NIL 2--3 170 275
2 12 306 35 2+ NIL NIL 190 140
3 9 260 23 2+ NIL NIL 225 200
1 9.8 328 19 1+ NIL NIL 256 190
2 8.8 355 45 NIL NIL NIL 160 230
1 10.5 178 28 2+ NIL NIL 196 190
0 11.4 291 34 NIL NIL NIL 236 275
2 15.2 212 31 1+ NIL NIL 176 236
0 10.2 265 24 3+ NIL 1--2 246 117
1 10.3 234 45 2+ NIL 1--2 156 245
1 8.5 343 25 3+ NIL NIL 123 159
2 9 324 33 2+ NIL NIL 256 365
2 11 205 35 NIL NIL 1--2 146 354
2 12 224 24 2+ NIL NIL 245 289
1 16 225 26 2+ NIL NIL 268 245
1 14 263 28 NIL NIL 2--3 256 354
0 12 254 24 1+ NIL NIL 245 174
2 10 263 29 2+ NIL 1--2 158 165
0 9 324 27 NIL NIL NIL 147 254
0 8.5 255 15 1+ NIL NIL 169 265
1 9.5 245 16 NIL NIL NIL 254 354
0 10.5 221 24 2+ NIL 1--2 148 265
2 11.5 265 28 3+ NIL NIL 168 354
0 8 235 39 NIL NIL NIL 157 398
2 10 236 34 1+ NIL 1--2 148 345
2 9 245 36 NIL NIL NIL 169 214
3 8 345 26 1+ NIL NIL 254 234
 101
2 9 234 25 NIL NIL NIL 268 125
1 9.5 275 29 1+ NIL NIL 254 145
0 9.5 310 34 1+ NIL 1--2 156 254
1 9.6 345 15 NIL NIL NIL 126 265
1 8.5 224 29 NIL NIL NIL 135 284
1 10.5 35 NIL NIL NIL 139 256
1 11.5 337 36 NIL NIL NIL 248 278
1 9.5 265 34 2+ NIL 1--2 103 226
2 8.5 452 26 NIL NIL NIL 254 325
3 9.5 482 18 3+ NIL NIL 105 254
1 9.5 358 17 NIL NIL NIL 278 259
0 9.5 254 16 2+ NIL 1--2 256 268
1 10.5 268 35 NIL NIL NIL 265 245
1 11.5 258 48 1+ NIL NIL 248 268
2 9.5 359 35 NIL NIL 2--3 128 254
0 10.5 354 16 3+ NIL NIL 269 226
0 11.5 365 39 NIL NIL NIL 268 175
1 10.6 369 31 2+ NIL 1--2 154 268
2 12.6 384 39 NIL NIL NIL 146 148
0 13.5 265 28 3+ NIL NIL 187 165
1 14.5 284 25 NIL NIL 1--2 198 247
2 10.5 289 24 1+ NIL NIL 278 269
1 10.4 274 29 NIL NIL NIL 245 258
1 10.6 268 27 NIL NIL NIL 245 265
3 9.5 247 26 NIL NIL 2--3 265 247
1 8.5 269 35 NIL NIL NIL 187 200
2 9 265 34 1+ NIL NIL 265 198
2 10 334 26 3+ NIL 1--2 248 234
0 12.5 333 38 NIL NIL NIL 149 230
1 11 368 26 1+ NIL NIL 198 265
0 14 354 35 NIL NIL NIL 247 265
1 8 348 34 NIL NIL NIL 239 365
0 9.5 369 39 2+ NIL 1--2 287 398
1 8.5 358 35 1+ NIL NIL 254 347
0 9 348 34 NIL NIL NIL 169 398
3 10 369 38 NIL NIL NIL 147 245
2 10.5 354 36 1+ NIL NIL 136 265
1 15 254 34 NIL NIL 1--2 258 254
3 14.5 268 39 2+ NIL NIL 146 245
0 12 269 38 1+ NIL NIL 149 248
1 13.5 247 34 NIL NIL NIL 168 365
1 16 269 36 NIL NIL NIL 247 354
1 14 248 25 3+ NIL 2--3 268 356
0 15 369 38 1+ NIL NIL 168 345
1 11 254 41 2+ NIL NIL 159 369
0 11.6 365 18 NIL NIL NIL 267 347
0 9 245 28 1+ NIL NIL 135 354
1 8.5 298 14 NIL NIL 1--2 124 368
1 9.5 269 26 1+ NIL NIL 121 368
0 9.4 248 35 2+ NIL NIL 246 347
2 9.6 369 36 NIL NIL NIL 248 126
1 8.5 247 34 4+ NIL NIL 245 200
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1 10 268 25 2+ NIL NIL 158 179
0 10.5 347 24 NIL NIL NIL 157 365
1 9.5 245 26 3+ NIL NIL 245 249
0 8.5 269 24 2+ NIL 2--3 158 268
0 14 248 35 NIL NIL NIL 268 272
0 12.6 269 35 4+ NIL NIL 147 295
1 11.2 248 36 3+ NIL NIL 168 275
0 15.6 269 24 2+ NIL NIL 268 286
3 14.5 248 15 NIL NIL 1--2 248 385
1 13.5 269 15 4+ NIL NIL 159 375
0 14 248 18 3+ NIL NIL 249 274
3 12.6 269 14 2+ NIL NIL 256 295
1 12.5 247 14 3+ NIL NIL 178 374
1 11.2 269 16 NIL NIL 2--3 214 195
1 11.5 247 18 4+ NIL NIL 256 185
2 10.5 269 17 3+ NIL NIL 168 176
0 10 247 25 NIL NIL NIL 254 254
1 14 269 14 1+ NIL NIL 185 398
0 12 356 26 3+ NIL NIL 238 385
1 9 356 28 1+ NIL 1--2 279 268
0 8.5 265 38 3+ NIL NIL 175 354
1 7 354 27 NIL NIL NIL 236 358
3 7.6 458 39 1+ NIL NIL 249 368
0 8.5 423 34 3+ NIL NIL 168 345
1 9.5 458 36 2+ NIL 2--3 215 398
2 9.5 325 35 NIL NIL NIL 265 345
0 9 425 39 1+ NIL NIL 132 275
0 10.5 365 36 3+ NIL NIL 245 265
0 11.5 248 34 1+ NIL NIL 269 274
0 10.6 256 32 NIL NIL NIL 128 295
1 12.5 348 31 1+ NIL 1--2 147 265
0 14 365 35 3+ NIL NIL 287 264
1 12 248 36 NIL NIL NIL 121 285
3 10 245 38 2+ NIL NIL 120 275
1 11 365 34 2+ NIL 2--3 256 294
1 15 398 36 NIL NIL NIL 232 245
2 10.6 489 32 2+ NIL NIL 169 216
0 12 458 34 1+ NIL NIL 274 354
0 13.5 259 36 NIL NIL NIL 147 215
2 10 348 32 1+ NIL NIL 269 285
1 15 368 39 1+ NIL 1--2 258 246
0 10.5 426 38 3+ NIL NIL 147 274
2 8.5 354 34 2+ NIL NIL 158 268
1 9 324 38 NIL NIL NIL 136 245
0 9.5 368 34 NIL NIL 2--3 248 274
1 9.5 364 38 NIL NIL NIL 239 245
0 9.4 364 25 NIL NIL NIL 158 245
2 9 314 24 3+ NIL NIL 165 158
0 12.5 325 27 1+ NIL NIL 175 256
1 12.5 325 26 3+ NIL NIL 146 245
0 10 369 26 NIL NIL NIL 247 265
1 10 368 25 NIL NIL 1--2 158 247
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2 10.8 347 28 NIL NIL NIL 169 185
1 12.6 369 29 NIL NIL NIL 269 184
0 12.9 347 17 4+ NIL NIL 248 145
0 8 368 14 2+ NIL NIL 156 261
3 9 325 19 1+ NIL 2--3 269 140
2 10 365 35 NIL NIL NIL 147 298
1 8 321 34 NIL NIL NIL 245 285
0 8 369 39 1+ NIL NIL 169 296
1 9.5 358 34 NIL NIL NIL 256 245
1 8.5 369 15 3+ NIL NIL 289 358
0 8.5 357 37 NIL NIL NIL 264 385
2 7.6 324 35 NIL NIL 1--2 247 396
1 7.6 369 36 2+ NIL NIL 251 374
2 9.5 354 34 1+ NIL NIL 236 284
0 8.5 368 25 NIL NIL 2--3 125 259
0 9.5 345 45 NIL NIL NIL 149 348
2 10.6 369 41 4+ NIL NIL 269 287
1 10.7 358 46 3+ NIL NIL 245 289
0 11.9 369 28 2+ NIL NIL 145 274
1 12.6 348 26 4+ NIL NIL 214 296
1 14.6 368 25 NIL NIL NIL 147 348
1 13.5 348 35 4+ NIL 1--2 145 175
0 14.5 358 39 2+ NIL NIL 136 185
0 12.5 256 38 NIL NIL NIL 248 195
2 11.5 356 34 2+ NIL 2--3 269 165
0 10.5 245 48 NIL NIL NIL 128 175
0 9 265 15 3+ NIL NIL 156 395
2 8.5 248 36 NIL NIL NIL 269 245
2 7.5 465 25 NIL NIL NIL 147 195
0 14.5 458 27 2+ NIL NIL 247 175
1 12.5 498 29 NIL NIL 1--2 187 185
1 12.5 245 26 2+ NIL NIL 147 165
1 11.5 354 31 4+ NIL NIL 258 200
1 10.5 365 35 2+ NIL 2--3 264 186
1 12.5 248 15 2+ NIL NIL 158 198
1 10.5 256 34 NIL NIL NIL 148 182
1 10.5 258 35 3+ NIL 1--2 269 245
1 11.5 358 38 NIL NIL NIL 247 169
1 10 365 38 3+ NIL NIL 145 175
2 9.5 248 35 NIL NIL NIL 258 186
1 9.6 236 34 NIL NIL NIL 247 195
1 9.4 245 39 NIL NIL 1--2 265 190
2 8.6 368 34 NIL NIL NIL 169 175
1 8.4 367 36 NIL NIL NIL 214 169
1 10.5 245 34 NIL NIL NIL 187 241
1 11.5 368 36 NIL NIL NIL 214 198
1 10.5 265 38 1+ NIL 1--2 258 176
1 11.6 365 34 4+ NIL NIL 157 175
2 8.5 458 31 NIL NIL NIL 214 215
2 9.5 368 39 NIL NIL NIL 269 189
2 10.5 352 25 3+ NIL NIL 168 215
1 9.5 321 35 NIL NIL 1--2 269 235
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1 12.5 326 24 NIL NIL NIL 247 175
2 12.6 356 28 NIL NIL NIL 158 198
1 14 245 39 NIL NIL 1--2 147 210
 
TGL HDL VLDL LDL ESTIMATE
D GFR BY
MDRD
FORMULA
STAGE 
OF CKD
SERUM 
CREATINI
NE
height weight waist 
circum
255 44 51 180 45 3 1.7 1.57 57 86
271 42 35 63 65 2 1.2 1.59 48 84
210 40 60 100 110 1 0.8 1.49 65 108
273 46 24 120 99 1 0.9 1.57 75 96
120 44 46 130 82 2 1 1.68 53 95
100 46 57 87 91 1 0.9 1.59 62 84
198 45 64 190 46 3 1.6 1.51 58 75
281 40 70 126 82 2 1 1.68 47 83
148 40 51 42 47 3 1.6 164 67 92
283 48 48 152 50 3 1.6 168 67 99
156 45 71 43 61 2 1.3 162 65 95
189 48 46 271 50 3 1.5 158 45 94
272 35 25 294 49 3 1.6 169 49 106
178 42 85 162 42 3 1.8 167 69 84
214 41 57 147 52 3 0.5 167 71 76
293 40 95 219 159 1 0.6 159 63 86
135 43 52 79 49 3 1.5 145 42 86
132 35 86 44 47 3 1.6 162 68 112
145 42 52 160 178 1 0.5 159 59 95
271 48 36 181 46 3 1.6 157 51 84
178 42 95 217 155 1 0.6 175 68 86
268 40 82 143 39 3 1.8 143 47 84
165 41 72 241 40 3 1.9 164 75 75
128 43 64 291 53 3 1.4 154 40 76
273 42 85 218 48 3 1.6 158 64 84
186 39 55 120 45 3 1.7 168 67 76
249 43 86 105 53 3 1.5 169 67 115
162 37 52 36 41 3 1.9 145 78 76
175 42 46 54 51 3 1.5 167 59 82
238 45 43 166 49 3 1.5 157 48 76
187 45 75 145 196 1 0.5 167 69 94
135 48 76 160 90 1 0.9 167 49 75
182 42 71 143 55 3 1.5 157 75 91
283 41 72 165 110 1 0.8 167 71 76
286 46 73 107 109 1 0.8 174 65 82
245 38 76 211 46 3 1.6 158 50 74
165 41 81 132 84 2 1 167 45 94
198 40 92 127 51 3 1.5 161 56 86
187 40 65 163 46 3 1.6 163 59 72
156 39 95 101 76 2 1.1 175 59 84
284 48 65 155 67 2 1.2 174 48 117
247 42 83 129 47 3 1.6 165 47 99
286 46 84 96 42 3 1.7 160 45 75
156 42 42 91 47 3 1.5 153 40 75
185 41 57 170 43 3 1.8 171 69 84
165 42 40 66 47 3 1.6 156 67 86
147 39 50 76 52 3 1.4 159 42 82
285 43 83 121 86 2 1 167 68 84
286 41 90 138 42 3 1.8 169 50 76
159 35 70 153 50 3 1.6 167 68 116
281 48 62 155 57 3 1.4 162 54 95
178 39 57 151 40 3 1.9 168 61 117
273 42 40 118 106 1 0.8 168 45 87
168 47 80 71 46 3 1.6 164 68 86
291 37 60 140 41 3 1.8 169 57 85
126 42 85 103 43 3 1.7 164 49 84
283 45 72 148 74 2 1.1 167 58 86
168 41 85 139 45 3 1.6 157 45 81
182 46 75 244 67 2 1.2 169 58 76
193 38 86 274 102 1 0.8 158 41 87
275 42 68 237 58 3 1.4 168 75 119
196 41 82 275 81 2 1 167 49 83
189 38 45 162 48 3 1.6 169 46 81
175 43 95 127 44 3 1.7 162 59 73
286 46 45 163 127 1 0.7 166 54 94
185 48 62 225 41 3 1.8 165 51 95
195 35 51 162 37 3 1.9 159 49 75
296 42 42 281 73 2 1.1 168 61 75
169 46 65 243 107 1 0.8 164 62 95
275 42 52 262 133 1 0.7 168 69 76
175 41 95 209 49 3 1.5 157 44 84
168 43 84 242 54 3 1.5 169 58 109
195 42 72 233 46 2 1.6 167 49 74
185 39 65 240 54 2 1.4 165 58 76
275 43 54 271 93 1 0.9 168 65 71
146 41 35 292 108 1 0.8 167 64 76
186 42 62 243 102 1 0.8 169 46 72
186 39 41 46 44 3 1.7 164 48 107
295 41 85 74 93 1 0.9 167 43 84
175 42 75 62 55 3 1.5 168 67 72
192 38 94 233 49 3 1.5 163 43 85
172 40 72 137 64 2 1.3 162 65 76
275 40 62 166 66 2 1.2 158 48 94
192 37 41 194 54 3 1.4 156 46 82
186 43 82 170 47 3 1.6 169 43 74
165 42 51 182 79 2 1.1 158 68 95
295 42 63 181 41 3 1.8 168 54 85
198 36 43 306 42 3 1.8 164 61 86
189 40 84 251 55 3 1.4 159 52 84
175 42 92 140 49 3 1.5 165 56 86
276 43 84 168 50 3 1.5 154 59 84
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169 35 75 264 69 2 1.2 159 68 82
298 43 92 60 52 3 1.5 167 65 84
159 40 43 102 99 1 0.9 158 57 86
275 42 96 38 45 3 1.8 152 69 106
168 42 52 160 71 2 1.1 164 54 87
268 38 84 276 54 3 1.5 169 69 89
169 40 72 273 49 3 1.5 152 41 76
137 43 56 169 91 1 0.9 148 56 87
254 40 83 231 88 2 0.9 147 51 75
169 41 42 275 149 1 0.6 156 68 84
189 43 61 264 38 3 1.5 156 75 86
245 39 72 234 40 3 1.4 167 64 82
265 41 68 289 72 2 0.9 169 60 76
284 42 54 249 41 3 1.4 158 58 75
158 38 67 160 33 3 1.7 149 68 86
269 43 84 138 28 3 1.9 158 67 94
258 40 75 159 77 2 0.8 159 58 83
213 40 83 172 48 3 1.2 167 53 86
148 38 92 135 81 2 0.8 148 51 95
175 40 56 168 66 2 0.9 169 53 75
168 41 91 153 99 1 0.7 168 67 92
154 41 53 181 29 3 1.9 145 57 93
134 40 82 172 69 2 0.9 175 58 85
256 38 84 123 66 2 1.1 168 61 72
284 40 56 120 37 3 1.6 157 61 74
158 43 85 226 38 3 1.5 175 58 106
273 40 75 100 31 3 1.8 145 58 89
245 39 68 178 41 3 1.4 148 54 87
165 42 72 132 42 3 1.4 147 64 86
238 40 63 171 67 2 0.9 143 51 84
275 39 73 156 38 3 1.5 156 68 109
283 42 61 142 115 1 0.6 158 68 93
192 40 84 150 36 3 1.5 167 68 74
215 34 57 147 71 2 0.9 157 67 84
189 41 83 121 48 3 1.2 143 56 76
283 39 75 44 42 3 1.4 168 68 82
175 40 84 132 30 3 1.8 154 41 85
238 45 81 119 78 2 0.8 154 58 76
216 46 68 151 34 3 1.6 159 55 94
276 42 86 119 112 1 0.6 157 46 105
186 48 68 69 40 3 1.4 153 68 114
234 40 94 50 78 2 0.8 152 57 86
169 41 71 33 41 3 1.4 154 55 87
215 36 75 150 107 1 0.6 158 65 84
147 42 54 44 81 2 0.8 157 71 82
283 41 87 170 51 3 1.2 153 68 106
158 40 56 189 78 2 0.8 157 69 87
263 43 46 207 55 3 1.1 168 59 82
273 40 58 147 38 3 1.5 154 54 107
168 40 68 250 84 2 0.8 157 68 89
256 42 62 281 48 3 1.2 153 67 82
136 36 85 275 38 3 1.5 152 61 106
268 42 65 267 69 2 0.9 158 67 85
86 43 64 177 31 3 8 4 59 6
167 1 84 134 3 1 9 7
83 75 233 67 2 7 6 1
41 0 71 176 3 6 4 8
246 64 83 68 0 9 5 9
172 42 6 14 2 1 43 58 76
275 39 95 162 70 2 0 9 49 52 82
62 2 35 271 113 6 57 9 4
8 64 7 54 3 1 1 54 49 83
53 2 5 91 36 3 1 5 43 73
47 0 82 73 4 6 68 46 95
9 43 57 195 31 8 45 46 94
172 38 9 68 40 3 1 4 5 49 92
45 1 42 312 7 2 6 42
73 41 83 21 8 5 67 46 7
172 2 53 00 31 8 65 41 75
1 3 5 82 48 108 1 6 43 65 5
14 37 7 5 8 2 1 5 4 4
62 40 1 4 106 1 9 59 9 76
9 68 92 3 1 5 57 45 87
83 37 75 74 105 9 45 0 71
36 0 45 13 7 1 1 7 6 7
43 65 7 73 1 1 1 41 4 76
162 43 64 0 3 5 4 54 5
175 45 84 5 5 52 7
82 0 6 70 53 6 43 1 74
185 42 4 47 59 4 71
173 41 7 6 58 5 67 60 73
93 98 50 57 5 9 59 72
172 2 82 5 48 3 1 3 58 7 7
193 42 57 70 104 1 0 6 4 47 87
172 39 76 26 8 7 7 46 71
75 92 66 157 1 0 4 57 86
162 40 68 68 118 1 6 8 46 75
43 0 7 62 94 1 0 8 7 49 5
149 43 94 78 6 5 52 56 76
53 3 2 54 44 6 3 8 74
16 3 68 04 35 3 1 47 1
12 38 84 13 71 2 0 9 68 48 7
1 5 0 75 65 49 3 4 73 5 76
48 0 85 73 38 6 48 57 85
186 2 81 87 156 1 5 3 60 4
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Sex- male -1, female-2 
Type of  diabetes mellitus  - type 1 DM- 1, type 2 DM- 2 
Treatment – 0- recently diagnosed, 1- on regular treatment  2- no treatment 
CHEST PAIN PALPITATION BREATHLESSNESS- 1-yes, 2- no 
POLYURIA POLYPHAGIA POLYDIPSIA- 1-yes, 2- no 
WEIGHT LOSS- 1- yes, 2- no 
PEDAL OEDEMA-1-yes, 2- no 
PRURITIS VULVA--1-yes, 2- no 
DIABETIC FOOT--1-yes, 2- no 
DIMINISION OF VISION—0- cataract ,1-vision loss, 2- no vision loss 
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ACUTE COMPLICATION -   1- diabetic keto acidosis, 2- hypoglycemia,  
3-cereberovascular accident, 4- myocardial infarction, 5- acute coronary syndrome, 
 6-hyperosmolar coma 
CAD / MI--1-yes, 2- no 
HT--1-yes, 2- no 
PVD--1-yes, 2- no 
 
BP (mean of 6 readings)  1- 130-139 / 85-89,  2- 140—150/ 90—99,  
3- 160 -179 / 100-109,    4- > 180  / >110, 5-  > 140    /   < 90 
POSTURAL BP DROP   
RETINOPATHY- 0 – not visualized, 1- normal, 2- back groundretinopathy,  
                                3- proliferative retinopathy 
Hb GRADE- 1->12 gm% , 2-< 12 gm% 
STAGE OF CKD (GFR)     1-  >90ml/hr,  2— 60- 89 ml/hr,  3- 30 -59 ml/hr,     
                                             4- 15-29 ml/hr,  5- < 15 ml/hr. 
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                                                         GLOSSARY 
 
ACR-          ALBUMIN CRETININE RATIO 
ARB-         ANGIOTENSIN RECEPTOR BLOCKER 
AER—       ALBUMIN EXCRETION RATE 
AGE-        ADVANCED GLYCAN END PRODUCTS 
ACE-        ANGIOTENSIN CONVERTING ENZYME 
 
BMI-          BODY MASS INDEX 
 
CAD -        CORONARY ARTERY DISEASE 
CVD-         CARDIO VASCULAR DISEASE 
CURES-     CHENNAI URBAN RURAL EPIDEMOLOGY STUDY 
CKD –        CHRONIC KIDNEY DISEASE 
CTGF-         CONNECTIVE TISSUE GROWTH FACTOR 
 
DN—           DIABETIC NEPHROPATHY 
DCCT-         DIABETES CONTROL AND COMPLICATION TRIAL  
DAG-           DIACYL GLYCEROL 
DKD-           DIABETIC KIDNEY DISEASE 
 
ESRD-        END STAGE RENAL DISEASE 
 
GFR-         GLOMERULAR FILTERATION RATE 
GLUT-      GLUCOSE TRANSPORTER 
 
IGT-          IMPAIRED GLUCOSE TOLERANCE 
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MA-         MICRO ALBUMINURIA 
MDRD-    MODIFIED DIET AND RENAL DISEASE 
MAPKS- MITOGEN ACTIVATED PROTIEN KINASES 
 
NON-STEMI- NON- ST ELEVATION MYOCARDIAL INFARCTION 
 
PKC-        PROTEIN KINASE C 
PVD--      PERIPHERAL VASCULAR DISEASE 
 
RAGE-    RECEPTOR FOR ADVANCED GLYCAN END PRODUCTS 
RAS-       RENIN ANGIO TENSIN SYSTEM 
 
UKPDS-  UNITED KINGDOM PROSPECTIVE DIABETS STUDY  
 
VEGF- VASCULAR ENDOTHELIAL GROWTH FACTOR 
